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ABSTRACT
An analysis of low- and semi-skill labor in biotechnology manufacturing was done
using case studies of eleven Massachusetts biotechnology firms. Four major questions
were asked: 1) How are production jobs generated in biotechnology at different stages of
product development? 2) What are the skill requirements for manufacturing jobs? 3)
How are women and people of color represented in manufacturing occupations? 4) How
good are biotech manufacturing jobs from the standpoints of compensation, opportunities
for advancement, and worker safety?
The results show that total job growth is modest by comparison with computers,
and that a growth spurt occurs between product testing and commercial license. Skill
requirements are significantly lower in commercial plants than in pilot plants. Women
are represented in laboratory and management occupations (with the exception of senior
administrative occupations) at similar levels to national averages, but people of color are
underrepresented. Biotech manufacturing jobs pay less than the average production
wage for all Massachusetts manufacturing industries. Opportunities for advancement are
more limited than traditional manufacturing industries. Workers may be exposed to a
number of biohazards, but the industry generally takes strong measures to prevent injury.
The findings illustrate the important differences in employment outcomes among
high tech industries (including biotech), and among biotech market sectors. They also
help point out important employment issues in the emerging biotech industry, such as
increased skill requirements for entry-level jobs, difficulty of access especially for people
of color, and the limitations to job advancement for non-degreed workers. These are
issues with which communities and state government must grapple as they struggle to
keep their economies competitive, promote jobs that serve local residents well, and
enhance opportunities for underserved populations.
Thesis Supervisor: Christopher Tilly, Visiting Professor
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Chapter 1
Introduction
Rarely has a new technology generated as much hope and controversy at the same time
as biotechnology has. One reason for hope is that biotechnology will make great
improvements in human health. However, many state leaders are excited about biotechnology
because of its promise to bring economic growth, especially employment. The following
research examines the employment characteristics of manufacturing in Massachusetts biotech
companies to see how large and widespread the employment potential of biotech really is.
What follows are the results and analysis of a study of the employment benefits to low-
and semi-skilled labor in biotechnology. The focus is on low- and semi-skilled workers
because they represent the largest segment of the workforce, and they have suffered from
recent changes in the availability and quality of work during the last several decades. We need
to better understand the implications of new technologies and industries, like biotechnology,
for this segment of the labor force.
Before summarizing the research questions and results, a short definition of biotech is
provided, along with a brief discussion of some of the larger and controversial issues
surrounding biotech. The controversies arise because certain biotech applications pose serious
ethical and environmental dilemmas. These issues should not be entirely overlooked when one
is considering how to support the industry to enhance employment, and other benefits.
WHAT IS BIOTECHNOLOGY?
People have been putting cells to work for centuries. Whenever we make beer or
bread, we harness the productive capabilities of yeast, and in a sense, are practicing
biotechnology. However, our understanding of plant and animal cells reached a critical
turning point in 1953, when Watson and Crick discovered the structure of DNA
(deoxyribonucleic acid), the molecule that carries the genetic information governing the
growth, maintenance, and reproduction of most living systems. This knowledge helped
scientists to understand how proteins (molecules composed of amino acids), and other naturally
occurring substances in the cell, can be used to treat and even prevent disease.
Biotechnology is the collection of techniques that use naturally occurring substances
and life processes to produce a wide range of products and services for applications in human
health, animal health, and agriculture. The best known of these techniques is called gene
splicing (or recombinant DNA), because it allows for the combination of segments of DNA
from different organisms. Microbes into which genes have been spliced may be commercially
valuable because they can produce useful proteins in larger and purer quantities than can be
obtained economically from other sources.
Perhaps the most successful example of a product obtained through genetic
engineering is human insulin. Prior to human insulin, the only other sources of insulin for
diabetic patients were pigs and cows. However, some people were allergic to the insulin taken
from these animals. When scientists first managed to get genetically engineered bacteria to
grow human insulin in a test tube in 1978, biotechnology achieved its first major victory.
CONTROVERSY
Biotechnology is beginning, and may continue to have a large, positive impact on
human health care in terms of diagnosing, curing, and even preventing disease. While other
technologies have had significant affects on the quality of human life, none has come so close
to controlling the biological basis of life itself. Because of its power, there are many debates
over how to use the technology, and how to eliminate or minimize its potential dangers.
Since the beginning, a number of controversies have surrounded biotechnology. Some
of these controversies are ethical in nature, while others are ecological. An example of an
ethical issue in biotechnology occurs in diagnosis. Biotechnology has enabled more precise
diagnosis of certain diseases based on the presence or absence of a certain gene, which is
associated with the disease. For example, should a person be told she has the disease if there
is no known cure, especially if it is not certain whether she will develop it? Can society
protect that same individual from possible discrimination (e.g. by insurance companies)?
Another set of controversies having to do with biotechnology involve the environment.
Microbiologists and ecologists continue to debate how to measure and manage the risk of an
accidental (or deliberate) release of genetically engineered microbes into the environment.
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Microbiologists say the risk is too small to measure and therefore insignificant, while
ecologists argue that the effects of releasing genetically engineered microbes into the
environment should be fully explored before it occurs. These and other issues will continue to
be debated, and must not be separated from public considerations of how to support
biotechnology.
BIOTECHNOLOGY AND ECONOMIC DEVELOPMENT
Economists and planners are also interested in biotechnology, because they associate it
with other high tech industries, which have bolstered the US economy and employed lots of
people during a time when many traditional industries were in decline. During the mid-80s,
industry forecasters predicted that the biotech industry would reach $100 billion in revenues
by the turn of the century. While this estimate may turn out to be overly optimistic, it
nonetheless caused many states to develop strategies to capture the economic and employment
benefits associated with biotech. Biotechnology represents a major technological innovation
that will give US companies an advantage over competitors in the world economy.
Competitive companies are expected to grow fast and employ lots of people.
Biotechnology is especially important to Massachusetts because the state has the
nation's third highest number of biotechnology firms. Estimates of total 1990 annual revenues
for these firms ranges between $263 million (Ernst & Young, 1990, p.89) and $1.3 billion
(Feinstein, 1990). Federal research dollars help fuel the science on which the industry is
based, and Massachusetts medical research institutions and universities get a large share.
Local receipts of federal funding rose from $317 million in 1981 to $503 in 1988 (Boston
Redevelopment Authority, "Outlook for the Nineties," 1990).
Biotech is also important because the state's economy is presently experiencing a severe
slowdown. Unemployment in Massachusetts averaged nearly 9.0% during the first quarter of
1991, nearly double the rate of the previous year and higher than the national average. Due to
its promise and good timing, biotech is attracting special attention from political leaders and
the media. Local leaders have encouraged the hope that biotechnology will save the state's
faltering economy. In a 1990 discussion paper, outgoing governor, Michael Dukakis, wrote
that,
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Massachusetts needs a new engine -- an industry, or several, that hold promise
of rapid growth in manufacturing as well as R&D, and which have the power to
spin off many times their weight in derivative jobs... Massachusetts should be a
world center of biotechnology, biomedicine, and related industries. We should be
a leader in manufacturing as well as research. And that is our goal. 1
Assumptions about job growth were reiterated more recently by Dr. James M. Howell,
consultant and former chief economist of the Bank of Boston. He argued that the
Massachusetts, and especially Boston economy has become a knowledge-based economy in
which young, high-technology firms are the engines of future growth. He counts
biotechnology among the high-technology firms.
As these firms are created, the achievement of high and rising levels of
productivity, the continuous upgrading of product design and quality and the
aggressive pursuit of new market segments will be quickly translated into new
jobs and higher incomes for residents of the city and state.2
RESEARCH FINDINGS
While it appears to be true that biotech firms are creating new jobs and paying high
salaries to their workers, on average, the implicit assumption is that biotech will be like
computers and generate lots of jobs and help the economy rebound. The following research
finds that job growth will actually be quite modest relative to computers, and that the average
wage for non-degreed production workers in Massachusetts biotech is less than the average for
all manufacturing industries in the state.
The majority of the Massachusetts workforce does not qualify for biotech jobs at
present, because they do not have the level of education required by firms. Most biotech jobs
require a bachelor's degree, which most Massachusetts workers do not have. However, jobs in
production operations in mature biotech companies typically require only a high school or
associate's degree.
1 "Winning the Nineties: Economic Strategy for Massachusetts." Prepared for the Governor's Economic Summit,
January 19, 1990, at MIT. pp. 8-9.
2 See Boston Redevelopment Authority "The Howell Report," November, 1990. p. 1 6 .
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Education is not the only barrier to job access. The current biotech workforce tends to
be more homogenous than the total workforce for all industries. People of color are virtually
absent from the laboratories, and are represented in very small numbers in production areas of
most biotech firms (greatly varying from firm to firm). Women are present in biotech
laboratories in larger proportions than other high tech industries, but are underrepresented in
senior management occupations.
Biotech is a new and unique industry. There are important differences among biotech
firms as well as between biotech and other high tech industries. In general, many of the
comparisons made between biotech and other high tech industries, in terms of employment,
are simply not true. States investing public money and hope in biotech may be sadly
disappointed. While biotech is a growth industry which will lead to certain public benefits, it
has special characteristics and needs that must be understood by those who wish to enhance
the benefits by supporting the industry. States (and cities and towns) must understand those
characteristics in order to effectively plan for biotech economic development.
Thesis Organization
I provide an overview of the research approach in chapter 2. It sets the context for the
study, introduces the research questions, reviews relevant literature, and describes the
methodology used. The research questions cover three, broad areas of employment: job
creation, access, and quality. Chapter 3 presents the results of my research on job creation.
Chapter 4 deals exclusively with job access from the standpoint of skills, while chapter 5 takes
up the question job access as it pertains to women and people of color. Finally, in chapter 6, I
present the results on job quality, including wages and benefits, opportunities for
advancement, and worker safety.
Each chapter analysizes the findings from the standpoint of low- and semi-skilled
labor. This analysis sets the stage for the final chapter, which pulls together the broad themes
of the research, and identifies several policy opportunities to promote and enhance
employment benefits for Massachusetts residents.
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Chapter 2
Research Overview
INTRODUCTION: THE NEW ECONOMY & EMPLOYMENT
The most recent thinking about economic development and employment usually begins
from the premise that American industries have lost their competitive edge (Harrison &
Bluestone 1982, Reich 1987, Osborne 1988, Blakely 1989). While the particular trends and
causes of America's current economic woes are widely debated, there is agreement that the
world economic system today includes many new strong competitors from Asia and Europe
who have cut into the profit margins of US corporations.
This new competition particularly hurt American corporations during the 1960s and
1970s. Firms restructured in response to the profit squeeze. Their strategies to cut costs and
regain profitability included measures to shed jobs, reduce wages, and relocate production off
shore (Harrison & Bluestone 1982, 1988). While the bad news is that we continue to lose
manufacturing jobs, the good news is that other sectors of the economy are adding jobs.
However, many new jobs in the service sector (e.g. food services and retail) do not pay as well
as manufacturing jobs, and sometimes do not provide full health coverage.
Two of the major outcomes of corporate and economic restructuring for labor have
been decreasing real wages and growing income inequality (Harrison & Bluestone 1988). As a
result, many Americans are struggling harder (and sometimes failing) to maintain the same
standard of living enjoyed by their parents. At the same time, the economy seems to be
producing two kinds of jobs: high pay for professional jobs and low pay for low skill jobs
especially in the service sector (Harrison & Bluestone, 1982). Therefore, economic
development strategies must not only consider job creation, but quality and equity to try and
offset the growing inequality (see Schramm, in Bruyn & Meehan, 1987).
High Tech Solutions: Employment for Whom?
Among the solutions being debated, including flexible production and education
reform, efforts at the state level have focused on targeting key industries, especially those in
the areas of high technology.' The most recent industry to be targeted for state support has
been biotechnology, which uses biological processes and substances to produce goods and
services (for a list of biotech products, see table 2.1). In its 1988 report, the Office of
Technology Assessment counts 33 states with specific funding allocations for biotechnology. 2
The importance of biotechnology in state economic development strategies was likewise
observed by researchers at the University of California, Berkeley in a national survey
(Blakely, 1988). One of the states banking heavily on biotechnology is Massachusetts.
There are two expectations typically associated with high tech strategies. One is that
high tech firms are innovative and competitive and will therefore help stimulate economic
revival for regions that host them (Osborne, 1989). The second is that these firms will
produce lots of new jobs (Birch 1979). The UCBerkeley survey of state biotechnology policies
confirmed the existence of this second expectation. Creating 'skilled-jobs' topped the list of
policy objectives of supporting biotech.3
However, there is an important distinction between research and development (R&D)
and manufacturing. Typically, we expect R&D to employ mostly high-skilled workers, while
manufacturing employs more low- and semi-skilled workers. If states are concerned with
creating jobs, we would expect them to target manufacturing as one of their top policy goals.
However, supporting biotech manufacturing, as opposed to R&D, was at the bottom of the list
of policy objectives in the Berkeley survey. Nearly one quarter of the respondents claimed
that biotech manufacturing (again, as opposed to R&D) is 'not very important' or 'not
important at all.'
It strikes me that states have their priorities reversed. Biotech R&D will generate
fewer jobs than manufacturing, and those jobs will not be accessible to low- and semi-skill
labor. States should plan for biotech manufacturing if they wish to help non-degreed labor.
Enlightened economic development practitioners generally argue that the goals of development
1 There are many definitions of 'high-tech.' I adopt the definition used by Markusen, et. al., in High Tech America,
which is to count those industries for whom the proportion of engineers, computer scientists, life scientists, and
mathematicians exceeds the manufacturing average.
2 See OTA (1988), p.5 5 . The count includes support for both academic research and commercial activities.
See Blakely, 1988, "The Search for a New Golden Goose," p.21. The sample includes 37 states.
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must go beyond promoting job creation. Employment strategies must also account for job
access. Of course, even if you have access, you have to worry about job quality and safety.
RESEARCH QUESTIONS: TARGETING BIOTECH PRODUCTION
Considerable attention has been given to R&D in biotechnology, but less seems to be
known about manufacturing. Yet presumably, the largest employment benefits will occur
when biotech firms begin manufacturing products for sale, which more and more firms in
Massachusetts anticipate doing in the near future.
Answers to employment questions are linked to product life cycle, firm strategies, and
location. By developing a set of case studies of biotech firms already engaged in production, I
will present information and analysis of four basic questions:
1. How are production jobs generated in biotechnology at different stages of product
development?
2. Where will production occur? Within Massachusetts or outside?
3. Who gets these jobs?
o How many production jobs are accessible to low- and semi-skilled labor at
present?
o Will access change in the future?
o Do women and minorities have access the production workforce?
4. How good are these jobs?
o How do firms compensate production employees?
o What are the opportunities for advancement?
o Are production jobs safe?
The answers to these questions are important to state policy makers, who must be
informed about the employment outcomes of biotech and of opportunities to enhance benefits
and upward mobility of low- and semi-skill labor.
LITERATURE REVIEW
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There is a substantial body of literature available on economic development and on
high technology in the United States. But there is very little written specifically about
biotechnology, or especially about its employment implications. However, from the existing
literature I have been able to assemble relevant information and predictions for my research
questions. I have organized the literature review according to the three employment topics:
job growth and location, access, and quality.
Job Growth
I explore job growth by examining three key factors that should predict both growth
and variation in production employment. The first is product life cycle. Jobs should be added
as the production process matures. The second is market segment. I use the two primary
market segments in Massachusetts biotech (therapeutic and diagnostic) to see if there are
significant employment differences. The third factor is corporate strategy. Not all firms have
growth as their first goal.
Current estimates of total employment in Massachusetts biotech range from 8,000
(Ernst & Young, 1991) to 13,600 (Feinstein, 1990), depending on how biotech is defined. The
number of production jobs in the state is estimated to reach 6,300 by 1993 and 25,000 by the
year 2000 (Feinstein, 1990). The surveys do not attempt to place these figures in a meaningful
context, such as comparing them with employment levels in other industries. Nor do they
explain how jobs are created at different stages of product development.
Traditional product cycle theory predicts that employment will be small when a
product is in the R&D stage, but increases as new markets are penetrated and as the
production process becomes standardized, and finally wanes as markets reach saturation and
consumers begin to buy substitutes (Vernon, 1966). However, Michael Storper has criticized
product cycle theory for being too rigidly deterministic (Storper 1985). He says the theory
abstracts away from the diversity of firms and the importance of historical conditions such as
the profit squeeze of the 1970s. Given this critique, employment growth in biotech
production should be more difficult to predict.
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Besides product life cycle, growth may vary according to market segment.
Biotechnology is typically broken into three market segments: therapeutics, diagnostics, and
agriculture. A national survey by Ernst & Young suggests that growth in production
employment will occur more rapidly with diagnostic products because of the shorter product
development which is more than half that of therapeutic products (Ernst & Young, 1987).
In addition to product life cycle and market segment, the number of production jobs
in biotech is likely to vary according to firm strategies, which are diverse. Ernst & Young
(1990) report five key strategies pursued by companies (see table 2.2). The common goal
among large firms is to become a fully integrated company, including developing their own
production infrastructure. The top two strategies among small firms are to develop products
which can be licensed, and to be acquired by another company. Neither of these strategies is
likely to result in big job growth in the near term.
Job Location
Employment benefits from biotech manufacturing will bypass Massachusetts residents
if companies carry on production activities outside the state. I will examine the location
patterns of R&D and manufacturing among Massachusetts biotech firms. The literature on
location is extensive and has gone through several revisions over the last couple of decades,
but it provides an interpretative framework for approaching biotech location patterns.
Traditional agglomeration theory predicts that innovation and manufacturing should
occur in urban markets to take advantage of external economies, such as lower transportation
costs, proximity to suppliers and markets, and labor supply (Richardson 1979). However,
since the 1950s, manufacturing operations have moved from core areas to peripheral areas.
This pattern has forced a rethinking of the theory.
Product cycle theory predicts that innovation will tend to occur in core urban areas
while production will locate in peripheral regions seeking lower production costs as well as
access to scattered markets. Dispersion has been aided by reduced transportation costs and
improvements in communication technologies. However, increased competition and profit
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squeeze have also heightened dispersion as companies moved operations to places where
production costs were lower (Harrison & Bluestone 1982).
The literature on high tech location acknowledges that location decisions have changed
with the advent of multi-establishment companies (Hymer 1979). In the late 60s, technical,
corporate, and administrative activities of high tech companies generally remained in close
proximity to one another (Malecki 1980). But since the early 70s, assembly operations have
been moved off shore to low wage countries (Glasmeier 1986).
One of the unique dynamics shaping location of production activities in biotech is the
tendency of firms to form alliances with larger companies. A study at Berkeley revealed that
of 27 collaborations between biotech firms and larger firms, none of the larger firms were in
the same state as the biotech firms (Blakely & Nishikawa 1990). Four of those collaborations
involved Massachusetts biotech firms, and all every case the partner firms were located in
outside Massachusetts -- in Delaware, California, Michigan, and London.
Blakely & Nishikawa reject the agglomeration and product cycle models of biotech
location in favor of a model that recognizes that both R&D and production occur concurrently
in separate, but allied organizations. They argue the model has three outcomes: 1) alliances
will preserve the separate functions of biotech firms (R&D) and their larger partners
(production & marketing). 2) Alliances simultaneously divide and bridge R&D from
manufacturing and distribution. They divide them in the sense that the activities are carried
out by separate entities in different places. They bridge them in the sense that the partnership
enables the product to go from R&D to production and marketing through the cooperation of
the partners. 3) The tendency for production and marketing jobs to migrate to peripheral
areas will largely occur through the existing or expanded labor force of the larger partners,
rather than through the biotech firms themselves.
In my research, I will explore the current location patterns of production facilities for
Massachusetts firms. While my research will not be an exhaustive look at the many factors
involved in location decisions, I hope to identify the trends in thinking among the firms in my
case study. In particular, I will describe the location strategies of firms in the state and assess
the impact of strategic alliances, looking for variations and patterns among firms.
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Job Access
I have two main concerns about job access. The first is to learn what the occupation
structure and skill requirements for production jobs are. None of the existing surveys have
adequately explored skill requirements. I am particularly concerned to know how many jobs
will be available to people with less than a four year degree, and how the skill requirements
change as the industry matures. My second concern is to find out the extent to which women
and people of color are represented in the production workforce. Again, none of the
preceding surveys have attempted to gather this kind of information.
SKILL
How many non-degreed (less than bachelor's) jobs are there in biotech, and are they
likely to increase in the future? Product cycle theory predicts that high skill labor is in
greatest demand when products are in the innovation stage, and that low skill labor is in
greater demand when manufacturing begins. Most people expect skill requirements for jobs in
biotech to be high, but it seems unlikely that they will remain high when companies begin
manufacturing. Little is known about how occupational structure and skill requirements
change as biotech firms become production enterprises.
In the final stages of high tech production, the work involves assembly of component
parts, and levels of skill are fairly low (Glasmeier, 1986). Massachusetts high tech industries
hired more unskilled workers than the average for all businesses (The High Tech Research
Group, 1984). At present, the numbers of non-degreed workers in Massachusetts biotech are
quite different. A recent survey estimated that three quarters of Massachusetts biotech jobs
require a minimum of four years college for entry-level positions (Massachusetts Board of
Regents, 1990). However, I would expect to see these proportions change with time as firms
mature and production becomes more routine. Unless production jobs hire employees with
less than four years of college, biotech jobs will be beyond the reach of the majority of
workers in Massachusetts.
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WOMEN & PEOPLE OF COLOR
The composition of the American workforce is changing. Women and people of color
represent the fastest growing segments of the workforce. This trend is expected to continue.
It underscores the need to design employment policies that are sensitive to demographic
changes. Since wage and employment differentials between men and women, and between
whites and people of color persist, access to jobs for women and people of color must remain a
goal of public policy. Are women and people of color working in occupations in the biotech
industry in equal proportion to their employment in similar occupations for all industries? To
date, no information on women and people of color in the Massachusetts biotech workforce
has been gathered and analyzed.
A 1983 study of biotech in Californian found that women were employed in the total
biotech workforce in equal proportion to their employment in all industries, but were heavily
overrepresented in clerical occupations (Markusen). Minorities constituted 21% of the biotech
workforce. However, Markusen suspected that counting foreign nationals as minorities
inflated this percentage. Similar results were found in data on Boston area high technology
firms (The High Tech Research Group, 1984). Of particular note was the finding that women
represented 57% and 71% of operator and laborer occupations respectively, which was higher
than for other industries. Blacks were employed at about one half their rate of employment
by other area private employers.
Job Quality
As mentioned above, average real wages have declined since 1973 and service jobs
(many of which are low paying and dead end) have outstripped manufacturing jobs
(traditionally high paying). Besides wages, job stability has become a concern for many
regions who have experienced job loss due to plant relocations. Policy makers have expanded
their job goals to include raising job quality. These goals apply equally to biotech job creation
strategies.
The distinction between good and bad jobs is open to debate. However, for purposes
of my research, I have chosen to investigate wages and benefits, opportunities for
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advancement, and worker safety. Little information has been collected about wages paid in
biotech production. The average hourly pay for most high tech production workers was found
to be less than that of production workers in manufacturing as a whole (High Tech Research
Group 1984). Similar comparisons between wages for production workers in biotech and
wages for production workers in all Massachusetts manufacturing should be possible.
METHODOLOGY
This section outlines the research hypothesis and explains why a case study approach
was used. It goes on to explain the basis on which firms were selected, and describes how
several problems were handled in choosing firms. Finally, it reviews the secondary sources
used to supplement the case studies.
Hypothesis and General Approach
While biotechnology offers potential long term economic benefits (such as innovation,
investment, employment, and taxes), not many production jobs will be created. Most of the
employment benefits will accrue to people with high skill. Moreover, jobs will not
automatically benefit low-skill labor, women, and people of color. Redistributing
employment benefits will require government intervention to enhance opportunities and
upward mobility.
Using primary data chiefly taken from surveys and case studies of Massachusetts
biotech firms, I will analyze the employment opportunities in production and make policy
recommendations. While case studies do not allow generalizations about the entire industry in
Massachusetts (nor about the nation), they provide more in depth analysis and qualitative
information than can be gained easily through surveys. Furthermore, I have chosen to cover
the subject of low- and semi-skill labor in biotech broadly rather than in depth. So inevitably
a detailed analysis of individual labor topics will be sacrificed for a presentation of the
broader picture.
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Selection of Firms
I had assistance in selecting firms from Fernando Quezada of the Massachusetts
Centers of Excellence Corporation (MCEC). His knowledge of, and contacts with the industry
were invaluable. I used two main criteria in selecting firms for the case studies. The first
criteria was to select the firms with large and mature production capacities. This criteria was
chosen because I assume we can learn more about biotech production from those with the most
experience. Furthermore, we can assume that younger firms in the same industry subsector
will probably follow production paths similar to those followed by the most mature firms.
The second criterion for the sample was to have a representative cross-section of each
biotech market segment: therapeutic, diagnostic, agriculture, and suppliers. However, in my
analysis, I concentrate on therapeutic and diagnostic firms for making comparisons. By one
estimate, therapeutic and diagnostic companies comprise 80% of all biotech companies in
Massachusetts. These two segments comprise 82% of my sample.
Although my sample of firms was not chosen randomly, it is a representative sample
on which to base case studies and draw general conclusions. I used all dedicated biotech firms
(or DBFs)4 in Massachusetts as the population for my sample. The best estimate of that
population is 116 firms. My sample included 11 cases (see table 2.3) which is just 10% of the
Massachusetts industry. However, if we use number of employees, my sample represents even
more than 10% of the population because the sample includes the largest firms in the state.
Other descriptive information about the age and size of firms in the sample is presented in
tables 2.4 and 2.5.
My main objective in these case studies was to understand the characteristics of
production jobs in biotech firms and how they vary with stage of development and market
segment. However, assessing production is difficult because only a few Massachusetts
companies are manufacturing for commercial sale at present. Most are manufacturing for
clinical research and expect to manufacture for commercial sale once their products are
4 I borrow this term from Blakely & Nishikawa (1990, p.8), who define DBFs as "entrepreneurial ventures started
specifically to commercialize innovations in biotechnology." The first DBF was Cetus, which was founded in California
in 1971. DBFs are distinguished from pharmaceutical or chemical companies, which generally are older and do not
exclusively use modern biotechnology in their production processes.
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approved for sale. My sample includes a couple of firms which are manufacturing for
commercial sale, or are fully equipped to begin commercial manufacturing pending product
approval. Other firms in the sample are manufacturing products for purposes of clinical trials,
which comes before commercial manufacturing.
Generally, I interviewed the senior person in charge of personnel, i.e. Vice Presidents
of Human Resources. In the case of several small firms, I was also able to interview the Chief
Executive Officer. I also interviewed other people as well, including industry consultants,
scientists, education and training people, biotech plant managers. These people helped give a
fuller perspective of the employment issues in biotech production. Twenty-four interviews
were conducted in person or by phone between February and April, 1991.
Secondary Sources
I found some useful information to help answer my questions in several surveys done
on Massachusetts biotech companies within the last couple of years. While I could have
elected to do my own survey, there were several reasons that prevented me. First, firms were
already complaining about being over-surveyed. Second, surveys would only provide fairly
narrow and mostly numerical answers. I wanted to understand the employment strategies
firms were using, and the factors influencing their choices. Finally, because a survey would
be resource and time consuming, I decided to use the existing surveys and then to supplement
them with interviews with a small sample of firms.
Basic information on firms including founding date, products, firm size, occupational
and educational structure of the workforce was available from directories and recent surveys.
However, surveys could not tell me how growth of production jobs grew and how the skills
changed, nor did they contain information about the gender and racial composition of a
company workforce.
Besides local surveys, I used findings from a 1980 study on California biotech firms
reported in a UCBerkeley working paper by Ann Markusen. As well, I cite one private
industry survey (Ernst & Young), which is taken annually of the biotech industry in the US.
Finally, I draw comparisons in most sections with other industries, such as drugs (SIC 283),
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which includes biotech therapeutical firms (SIC 2836) and biotech diagnostics (SIC 2835). I
also make comparisons with computers and semiconductors (SIC 3571,-2,-5,-7, and 367).
These sources are taken from the US Bureau of the Census and Massachusetts Department of
Employment and Training.
Table 2.1
Biotechnology Products
on the US Market
Treatment or Use (year first approved)
HUMAN HEALTHCARE
Alpha interferon
Erythropoeitin
Gamma interferon
Human growth hormone
Insulin
Tissue plasminogen activator
Vaccines
Monoclonal antibodies (MAbs)
DIAGNOSTIC TESTS
(MABS and DNA probes)
AGRICULTURE
Animals:
Vaccines
Diagnostic tests
Plants:
Diagnostic tests
FOOD PROCESSING
Diagnostic tests
Chymosin or renin
OTHER
Transgenic mice
Luciferase TM
hairy cell leukemia (1986),
Kaposi's sarcoma (1988),
non-A non-B hepatitis (1990)
anaemia associated with
kidney disease (1989)
chronic granulomatous disease (1990)
dwarfism (1996)
diabetes (1982)
dissolve blood clots (1987)
hepatitis-B (1986)
treat kidney transplant
rejection (1986), purify
blood clotting agents (1987)
diagnose pregnancy & fertility; bacterial
and viral infections; genetic deseases
DNA fingerprinting; forensic
and paternity testing, etc.
colibacillosis or scours (1984),
pseudorabies (1987)
bacterial and viral
infections, pregnancy,
presence of antibiotic residues
diagnose plant diseases (e.g.
turfgrass fungi)
diagnose food and feed contaminants (e.g.
salmonella, aflatoxin, listeria)
enzyme used in cheesemaking (1990)
cancer research
detection agent used in food
and medical diagnostic tests
Source: U.S. Industrial Outlook, U.S. Dept of Commerce, 1990.
Product
Table 2.2
STRATEGIC GOALS OF US BIOTECH
by Company Size
Company Size ----- Strategy -----
(percent of
companies) 1 2 3 4 5
Small 66% 41% 59% 51% 38%
1-50
Mid-size 65% 63% 31% 35% 29%
51-135
Large 40% 68% 16% 16% 80%
136-299
Top Tier 44% 78% 13% 0% 90%
300 + emp
All Companies 61% 51% 46% 40% 31%
Source: Ernst & Young, Biotech 91: A Changing Environment
Notes: Strategy 1: Develop products that corporate alliance
partners will market
Strategy 2: Become fully integrated company
Strategy 3: Establish enough value to attract
an acquisition
Strategy 4: Establish enough value for an initial
public offering (IPO)
Strategy 5: Develop core technology for licensing
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Table 2.3
MASSACHUSETTS BIOTECH SAMPLE
By Market Segment
(11 Companies - 1991)
Product Sector Thesis MBC Survey 5 E&Y Survey 6
% of sample % of sample % of sample
Therapeutic 64% 41% 35%
Diagnostic 18% 39% 28%
Agriculture 18% 8% 8%
Suppliers -- 12% 29%
Total 100% 100% 100%
5. "An Assessment of
October, 1990.
the Massachusetts Biotechnology Industry", by Peter Feimstein Inc.,
6. "Biotech 91: A Changing Environment," by Steven Burrill & Kenneth Lee, Jr. for Ernst &
Young, 1990.
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Table 2.4
MASSACHUSETTS BIOTECH SAMPLE
By Date of Founding
(11 Companies - 1991)
No. of Firms Before 1980 After
Total = 11 1980 1985 1986
Firms 9.1% 54.5% 36.4%
Source: Case Studies (1991)
Table 2.5
MASSACHUSETTS BIOTECH SAMPLE
By Size of Company
(11 Companies - 1991)
No. of Firms Small Mid-Size Larger Top Tier
Total = 11 1-50 51-135 136-199 300+
Firms 18.2% 27.3% 18.2%
Source: Case Studies (1991)
36.4%
Chapter 3
Job Creation
INTRODUCTION
Recent estimates of biotech employment and future growth in Massachusetts threw
cold water on expectations raised by the outgoing Dukakis administration that biotech would
save the state's faltering economy and put people back to work. While biotech will produce
needed jobs during hard economic times, it will not match the employment levels of computer
and semiconductor industries.
This chapter explores the job creation process in biotech production, where most low-
and semi-skilled jobs are created. Recent surveys provide current and future estimates of
production jobs, but they do not explain how jobs are generated at different stages of product
development. The major findings in this chapter are that:
1) Biotech production does not employ large numbers of people.
2) Production occurs in three distinct phases -- research & development, clinical trials,
and commercial manufacturing. It takes place at the lab bench during R&D. Then
during clinical trials, it typically moves into a separate space, or pilot plant, within the
same facility. Finally, commercial manufacturing often requires a separate facility.
3) The number of production jobs increases between R&D and clinical trials, and skill
levels begin to drop. The average pilot plant employs slightly more than 40 people,
2/3 of whom have at least a bachelor's degree.
4) For a given product, the number of production workers required for commercial
manufacturing is not necessarily higher than for manufacturing in the pilot plant
(depending on automation and potency of product). However, the majority of jobs in
commercial manufacturing do not require 4 years of college. The average commercial
plant employs 53 persons, almost 60% of whom have less than a bachelor's degree.
5) Some firms may pursue strategies that do not lead to growth in production employment
6) Production is already beginning to leave the state, and many firms will be making
critical location decisions in the next 18 months.
Chapter 3 is organized in several sections, beginning with an overview of biotech
employment in the US and in Massachusetts. Next, the focus is given to production
employment. National and state data on production jobs is reviewed next, and that is followed
by an analysis of the job generation process at the plant level for both therapeutic and
diagnostic products. The fourth section explores several limitations on employment growth,
including firm strategies and location decisions. Issues of skill requirements, access to jobs by
women and minorities, and job quality are considered in later chapters.
Does Biotech Create Lots of Jobs?
Counting jobs in the biotechnology industry is difficult. First of all, biotechnology is
a process used in many industries: primarily pharmaceutical, chemical, food and agriculture.
Second, there are companies which were founded with the sole purpose of exploiting
biotechnology processes (referred to in this study as dedicated biotechnology firms, or DBFs),
while other companies may use biotechnology processes for some, but not all of their products.
Finally, there are companies which make equipment used in the biotechnology industry.
The decision about which companies to include in estimating total jobs, and whether to
count all employees or just those who are engaged in biotech processes, leads to different
estimates of employment. For example, there are two annual estimates of biotech employment
at the national level (see tables 3.1 and 3.2). The Bureau of the Census estimates that in 1990
there were 28,700 employees in diagnostic (SIC 2835) and non-diagnostic, or therapeutic (SIC
2836) sectors. Ernst & Young, a private consulting firm serving the biotech industry,
estimated that there were nearly 50,000 employees in biotech in 1990. The truth depends on
the biotech definition used, and on the availability and believability of data for the categories
included.
Based on the government's 1990 estimate, biotech in the US is very small -- it
represents only 16%, by employment, of the entire drug industry -- and even smaller
compared to computers and semiconductors, which employed almost 28 times as many people
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in 1990. However, since 1988, computers and semiconductors have shown job losses, whereas
biotech (and most of drugs) added jobs. Computers and semiconductors are mature industries,
while biotech is in its infancy.
Official government estimates of employment in biotech in Massachusetts are not
available, but several surveys have attempted the task. The local estimates range (see table
3.3) from 13,600 to 17,585. Regardless of the estimate used, biotech represented less than half
of one percent of total employment in Massachusetts in 1990 (see table 3.4), and
approximately 6.4% of all high tech employment. High tech employed 212,200 people in 1990,
which was down from 238,600 in 1988 (see table 3.5). Job losses in high tech between 1988-
90 were twice the estimated number of total employees in biotech as of 1990. Even if the
most optimistic projections for growth of Massachusetts biotech are correct and employment
reaches 80,000 (see table 3.3) by the turn of the century, biotech will employ barely half of
what high tech employed during the 1980s. 1 Biotech employers are the first people to agree
with this assessment:
[Biotech] is not going to be the kind of industry, from a production staffing
point of view, that will be equivalent to the DECs and Wangs of this world. It
isn't a labor intensive kind of thing. A lot of it is automated. You're harvesting
your product from processes that don't require an assembly line type of an
approach.
JOBS IN BIOTECH PRODUCTION?
Estimates of the number of biotech production jobs in the US in 1990 were 14,300,
exactly half of all biotech jobs (see table 3.6). In Massachusetts, Feinstein estimated that 3,264
1 Indirect employment from biotech companies in Massachusetts may be significant someday. However, it does
not appear to be a major economic phenomenon at present. Among the three largest biotech firms in the study (and in
the state), none had a major product licensed for sale in the US, so sales to local firms (forward linkages) are
insignificant as of 1991. Firms were asked to estimate the percent of total annual purchases (supplies & services in
dollars) derived from Massachusetts firms. Only one out of three firms could provide a rough estimate, which was more
than 35% of annual purchases. Aside from capital equipment, the largest annual purchases of supplies are typically for
scientific and production equipment and chemicals. All three firms said they buy from the same 3 major suppliers:
VWR Scientific, Fisher Scientific, and Baxter Scientific Equipment. None of these firms is located in Massachusetts,
although they have distribution offices located here. Average employment at each Massachusetts distribution company
is estimated to be about 30 employees.
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of 13,600 of biotech jobs were in production, which represents one quarter of the biotech
workforce. The proportion of production jobs to all jobs in the national estimate may be
inflated due to including older companies which have larger production workforces, and are
counted because some fraction of their business is biotech. Feinstein forecasts that production
jobs in Massachusetts will increase 686% by the year 2000. This means that the number of
production jobs might increase from 3,264 (24% of total biotech workforce) in 1990 to 25,655
(32%) jobs by 2000.
PRODUCTION OCCURS IN THREE STAGES
Production occurs in three distinct phases during the life cycle of a product. Between
each phase, the number of the employees changes, with the largest increase typically occurring
during scale-up, the period when the company goes from producing small to large quantities
of a product. Not all products are alike, and so not all production processes are alike. There
are significant differences between therapeutic and diagnostic products, that mostly have to do
with regulatory controls and the complexity of the production process. Second, there can be
variation among therapeutic products due, again, to regulatory controls, but also to product
concentration and potency, and automation.
Each of these characteristics influences employment and will be discussed in this
section, but first, we should briefly review the production process itself to provide
background. In so doing, I will use the therapeutic market segment as the basis for the
description, because it helps to clarify the different employment outcomes. However, later, in
the section, an example of employment growth during the product development cycle of a
diagnostic product will be given.
Like all drugs, biotech products are heavily regulated. These regulations demarcate
the three phases in the production process. Before a vaccine or therapeutic treatment can be
sold in the US, a company must demonstrate that it is safe and effective, and can be
manufactured consistently. Before a drug can be tested in clinical trials, an Investigational
Drug Application (IND) must be filed with the Food and Drug Administration (FDA). If tests
show that the product is safe and effective, then a second permit, the Product License
Application (PLA) is granted. In addition, the manufacturing process itself must be validated
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to show that the product can be produced consistently and meet current good manufacturing
practices (GMPs). After PLA and validation, then the product can be made and commercially
marketed (see table 3.7).
1) RESEARCH & DEVELOPMENT: LABORATORY BENCH
The first stage occurs during R & D when small quantities of product are needed for
laboratory investigations. Quantities, in the range of 1 - 50 litres, can be produced at the
same lab bench where R&D occurs. This phase may last up to a year or more for a
therapeutic.
There are usually fewer production steps in R & D than later stages, since the end
result is not a finished product. Steps include: i) cell culture and fermentation, where desired
cells, or cell parts (e.g. proteins), are grown, ii) primary recovery, where the product is
captured, and iii) purification of product into bulk form. Production is usually carried out by
several scientists and engineers, with assistance of one or two non-degreed people, who wash
glassware, care for laboratory animals, and/or prepare solutions. Total staffing is probably not
more than 5 persons.
2) CLINICAL TRIALS: THE PILOT PLANT
The second stage occurs after an IND permit is granted, and can take up to several
years. At this time, larger quantities of product (50 - 100 litres, depending on the potency)
are needed to supply clinical trials. Production may expand to several benches within the lab,
or move into a separate pilot plant, usually in the same building. Pilot plants are not large.
Generally, they range in size from 5,000 to 20,000 square feet.
Process steps begin to increase in the pilot plant, adding to those mentioned above a
iv) formulation step, where the bulk product is stabilized for delivery into the blood stream,
v) a filling step, where the product is put into one of several forms (e.g. capsules, vials, freeze
dried, etc), and vi) a packaging step, where product is boxed, labelled, and shelved. The
production process in the pilot plant is still undergoing development and change. It is not yet
routine.
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At this time, a plant manager is hired, along with several supervisors, as many as 10
process operators, a quality control (QC) specialist, one or two filling technicians, a couple of
utility specialists who maintain boilers and other equipment, and one to two people to handle
packaging and shipping, if required. Total staffing might reach as much as 50 people, most of
whom will be degreed. Based on a local sample, the average workforce in the pilot plant is
estimated at 41 employees, two-thirds of whom are degreed (see table 3.7). Because
economies of scale have not been fully achieved, pilot plants are often more labor intensive
than commercial facilities.
3) MANUFACTURING: THE COMMERCIAL PLANT
When a PLA permit is received, production goes through scale-up, during which time
the biological, chemical, and engineering issues associated with increasing production by
factors of 10X, 100X, or even 1000X, are worked out. This increase from the pilot scale is
usually not linear, however, and presents serious technical challenges. Typically, a separate
and dedicated commercial facility is established in the range of 50,000 to 200,000 square feet.
While fermentation volume may reach as high as 100,000 litres, scale-up does not
mean that the number of employees increases in proportion to the product. The same person
who operated a fermenter with a 10 litre capacity, can be trained to operate a fermenter with
a 10,000 litre capacity. Process steps do not change appreciably, but are made routine and
followed religiously to avoid the risk of losing federal license to manufacture.
After the commercial facility is created, the pilot facility is likely to be assigned to a
new product for process development. Some employees from the pilot facility may move to
the commercial facility, but most of the staff for the commercial facility will be new hires.
Additional utility technicians, process operators, and packaging and distribution people will be
added. Total employment may increase beyond the pilot plant. Or it may actually decrease
due to economies of scale and automation. Based on estimates from several firms, the average
employment in commercial plants would be 53 persons (see table 3.8).
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Other variables affecting growth
There are a number of variables which affect employment in the biotech plant.
Broadly, these variables fall into two categories: those over which companies do not have much
control, and those over which they do exercise control. In the first grouping are those
qualities inherent in the product (concentration and purity) and regulatory requirements. The
second grouping includes things like automation, company goals, and strategies.
Product Concentration & Differences
The biotechnology revolution enabled certain products to be produced in much greater
quantity, concentration, and purity than were possible before using traditional processes. In
this respect, the technology is labor saving. If a product is very potent to begin with, then
fewer employees are needed to grow adequate amounts of it. A highly concentrated product
may actually require fewer employees when it is manufactured in a commercial facility than
in the pilot plant. In other words, if 1,000 effective doses can be obtained from 1 litre of
material, versus 10 doses, then scale-up allows fewer employees to produce large quantities of
product.
Some products are more labor intensive than others, because they require extra
processing steps or because of special regulations pertain to their manufacturing. Some
products are simply difficult to make because they require extra steps to process and purify.
Occasionally, chemical modifications must be made. All of these additional steps require extra
hands, and so increase the number of employees who will be hired.
Other products require extra processing steps because of regulations. This is the case
with biopharmaceuticals, which are injected into the bloodstream. The FDA requires
additional steps and precautions to ensure purity and consistency. As a result, more inspectors
must be hired, as well as quality control and quality assurance personnel. By contrast,
manufacturing antibiotics is simpler because they are not as regulated (see table 3.9). One
plant manager estimated that biopharmaceuticals employ 1/3 to 1/2 more workers than
antibiotics.
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Regulations matter in diagnostic products too. Those used outside the body (in vitro)
are not as strictly regulated as those used inside the body (in vivo). The other difference
between diagnostic and therapeutic products is that diagnostics tend to have more pieces to
package. Therefore, diagnostic products often hire more people for packaging, distribution,
and warehousing. The addition of employees for a diagnostic product are shown in the typical
Table 3.10. Most of the 11 people added in the commercial phase are assemblers.
Automation
The incentives to automate biotech production include reducing the labor bill, and
improving consistency and accuracy of data collection used to show compliance with federal
regulations. Everyone interviewed said that automation is widely practiced, and likely to
increase in the future. One employer explained the incentives and limitations of automating
production for her company as follows:
The number of people you decide to hire in production and how much you
streamline depends on how much you automate. The issue we have with
automation in diagnostics is that you have a short product life cycle, which
discourages automation. Having said that, I would say that our products arefairly automated... We have chosen to automate first those processes that are the
most labor intensive that we saw ourselves continuing for several years... [But]
in real small lots you still fill by hand.
Company Strategies & Alliances
A common goal of the biotech firms, who started 10 years ago, was to become an
integrated company, including manufacturing, marketing, and sales infrastructures. However,
the Ernst & Young survey reveals that company strategies are more diverse today. Not all
companies do plan to become fully integrated. Instead, some firms say their goal is to license
technology. One CEO referred to these companies as 'research boutiques.' They engage
exclusively in research, and ignore manufacturing altogether. As a result, they do not plan,
nor show much employment growth. Some companies even claim their goal is to 'establish
enough value to attract acquisition' (Ernst & Young, 1990, p.26 -- see table 3.11).
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One of the most common strategies used by biotech firms is the strategic alliance.
Alliances are struck for purposes of research, production, marketing, and/or sales. US biotech
companies say they engage in three strategic alliances on average (Ernst & Young, 1990, p.39).
Most alliances are formed in order to take advantage of the partner's marketing capability, but
17% of the companies use alliances for manufacturing (see table 3.12). Production
employment in Massachusetts is hindered when a firm chooses to license its technology to a
firm outside the state, who manufactures that product in its own facilities. Currently, most of
the products developed by Massachusetts biotech firms are being manufactured outside the
state by large pharmaceutical and chemical companies. 2
Licensing may decline in the future if companies develop internal production and
marketing capabilities of their own. However, if the strategy becomes a permanent fixture (as
warned by Blakely and Nishikawa, 1990), then we are likely to see production growth in
Massachusetts inhibited to a degree. One experienced CEO, observed that his company's use
of alliances is changing.
Four or five years ago, 90 percent of what we were working on in the research
pipeline had already been licensed. Today, that's flipped. We own worldwide
rights to 90 percent of our R&D today. We'll do more licensing, we'll do more
deals, but they will be more strategically than economically driven. James
Vincent, CEO, Biogen, (Ernst & Young, 1990, p.103).
In reflecting on what he would do differently today, another CEO from Massachusetts, said,
I would have insisted on complete manufacturing rights on all licensing deals,
and have moved faster to retain clinical development control. Gabe Schmergel,
CEO, Genetics Institute, (Ernst & Young, 1990, p.103).
LOCATION
Alliances are not the only strategy currently limiting employment growth in biotech
production in Massachusetts. Some firms are choosing to establish manufacturing facilities
outside the state. There are also signs that firms will do their manufacturing off shore. Three
2 Information obtained from company annual reports.
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of the eleven firms participating in this study have manufacturing facilities, or warehouses in
other states, and three have manufacturing facilities overseas (see table 3.13).
Despite the beginnings of decentralization, most biotech firms are still concentrated in
the Cambridge area, because they want to remain close to the universities where many of their
founders teach, and where they can tap scientific advances as soon as they happen.
We are and will always be a science driven company. Not quite half of the founders of
this company are still with Harvard and MIT. Having the ability to access the scientific
innovations that are going on in the academic research laboratories is important to us.
But Cambridge may not be ideal for manufacturing, because land is scarce and expensive.
Companies also mention their concern about the regulatory environment.
Cambridge is a very constraining environment. Are we going to have an environment
that is conducive to setting up a production facility, or are we going to have
environmental issues that would be too overwhelming to allow us to stay here, versus
going to Rhode Island, New Hampshire, Puerto Rico, or Ireland. Our preference would
be closer proximity than to have to get on an airplane to go see the production facility.
Cambridge is not the only hot spot in Massachusetts. Worcester, which boasts several
universities and a teaching hospital for medicine, is home to half a dozen biotech companies.
Town leaders have put together a set of regulations that companies find attractive. With help
from the state, Worcester created a science park for biotech companies. Recently, BASF, one
of the world's largest corporations chose Worcester to establish their newly created bioscience
laboratory. Local BASF officials speak with enthusiasm about Worcester.
Worcester had the infrastructure that no one else had. It had the Biotech park all set up
to lure biotech companies. They had the legislation in place. Worcester city fathers and
business people were ready for biotech -- encouraging, and wooing biotech. It was
ready made for us. We didn't have to wait for regulations and laws concerning biotech
research. It was all there, and they wanted it. The Worcester community is extremely
supportive.
While Massachusetts still retains its appeal as a hotbed for science, firms are looking
outside the state as they mature, plan production facilities, and plan strategies for entering
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world markets. They do not have to wait to learn what other states and countries have to
offer. Every person interviewed for this study mentioned that they were regularly contacted,
and occasionally offered tempting deals, by more aggressive governments.
There are tradeoffs to keeping operations in the same vicinity. One executive
expressed the view that commercial production facilities should be far enough away from
R&D to prevent the R&D from influencing production.
Once you're up doing commercial manufacturing, you want to be sure you're not doing
research. A lot of people argue the opposite. They say they like to have their
manufacturing close to their R&D so it will be easier to put in different new
technologies and techniques. I think that's dangerous, because when you're doing
manufacturing on a commercial scale, you want to make sure you do it the same way,
every day, all the time. So you don't want to have the research, innovative influence on
that. You want to do that in a pilot scale to get everything worked out, because going in
to change your process and getting the FDA to accept it is not trivial.
By no means is this philosophy true for every company. One of the state's largest
therapeutic producers has kept all of its facilities in Cambridge. A production manager there
said he would not want a dedicated commercial facility to be more than one hour away from
the R&D operations, because of the need for frequent visits. However, two production
managers from other therapeutic companies were not adamant about keeping facilities in the
same state.
Because the regulatory requirements for diagnostics are less severe, these companies
seem more content with present facilities. Both diagnostic firms in the sample have all of
their operations contained within one building. A CEO from one of these firms offered a rule
of thumb about expansion and relocation for a diagnostic company:
For a diagnostics business up to $50 million in sales, I'd just as soon have it all under
one roof. I think that there are significant benefits.... I mean these aren't anvils we're
making, so you just can't ship a blueprint up to Ottumwa and have them read the
blueprint and go make the anvils. These are very delicate biological systems, and
they're changing all the time... and from time to time they don't work... So to be able to
have the development scientist and the production scientists sit down and do problem
solving together without having to charter airplanes -- I think -- is a distinct benefit.
Beyond that, you might have administration and distribution under one roof in
Massachusetts, and take both production and development and put them in Bellbrook,
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Ohio or somewhere. But I think I'd keep those two (production and development)
together, and this is based on my experience at [another diagnostic firm], where one of
my predecessors decided to split up R&D and production and it was disastrous. It
almost spelled the end...
Agriculture may be different from therapeutics and diagnostics. While most of the
agricultural biotech firms in Massachusetts are still in R&D, Biotechnica International, the
state's largest player in agricultural biotechnology, recently decided to relocate to the midwest.
The only agricultural company in this study said, unequivocally, that when the company
reaches commercial production for their agriculture product,
... we would not do manufacturing in Massachusetts. One of the issues is raw material.
The material we use is a corn gluten protein, so we want to be close to where they mill
the corn...
Europe and Puerto Rico are likely to be winners of biotech production facilities in the
future. One CEO explained the reason his company opened shop in Europe:
If you are to succeed, you must access that marketplace. To do so, a company
must have a manufacturing presence in Europe. It's much easier to get products
into the international markets if they're made locally there. US made products
take much longer.
Puerto Rico is equally attractive to companies because of tax advantages and a large
pharmaceutical infrastructure on the island. More than 85 pharmaceutical companies have
operations in Puerto Rico, manufacturing about half of all pharmaceutical products sold in the
US. 3 In the Boston Herald story, one company executive said that:
We would jump to Puerto Rico in a New York second if Massachusetts does not
provide us with some sort of incentives, because Puerto Rico does.
3 Puerto Rican Economic Development Administration, cited in Boston Herald, 4.23.91. p.2 8 .
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CONCLUSIONS
The major implications of this chapter's findings are:
1) The absolute numbers of production jobs created by biotech in Massachusetts are quite
small. Even the most optimistic forecasts, if they come true, project that biotech will
employ less than half of what computers and semiconductors employed in the state
during the 1980s.
2) Biotech production creates more jobs than R&D, and it mostly creates jobs for low-
and semi-skill labor. Therefore, if the state is going to target this industry, it must
develop effective strategies for supporting biotech manufacturing.
3) The critical growth in production for non-degreed labor comes as clinical trials end,
and scale-up to commercial production begins.
4) Employment volume varies with product, market segment, and firm strategy. Some
companies are more likely to generate jobs than others.
5) Scale up is also the time when companies consider establishing production facilities.
And there is a good likelihood that companies will set up production outside the state.
However, some companies realize there are incentives to keep facilities in state.
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Table 3.1
Total Employment in U.S. Biotechnology &
Other High Tech Industries
Actual and Estimated, 1987-1991
----Percent Change-----
Employment 1987 1988 1989 1990 1991 1987- 1988- 1989- 1990-
1988 1989 1990 1991
Total employment (000) 172 174 176 178 181 1.2% 1.1% 1.1% 1.7%
2833 Medicinals & botanicals 11.6 11.4 11.7 11.6 11.8 -1.7% 2.6% -0.9% 1.7%
2834 Pharmaceutical preps 132 135 136 138 140 2.3% 0.7% 1.5% 1.4%2835 Diagnostic substances 15.4 14.5 14.8 15 15.1 -5.8% 2.1% 1.4% 0.7%
2836 Bio prod ex diagnostic 13.3 13.2 13.4 13.7 13.7 -0.8% 1.5% 2.2% 0.0%
3571, -2, -5, -7
Computers & Peripherals 286 289 289 277 270 1.0% 0.0% -4.2% -2.5%367 Electronic Components 547 561 533 520 506 2.6% -5.0% -2.4% -2.7%(Including Semiconducters)
Source: U.S. Department of Commerce: Bureau of the Census; International
Trade Administration (ITA). Estimates and Forecasts by ITA
1988 Advance data from the 1988 Annual Survey of Manufactures.
1989 Estimate
1990 Estimate
1991 Forecast
Table 3.2
Regional Distribution of Biotech Employees
(1990)
Region Number of Employment
Employees in percent
San Francisco Bay Area 12,456 25.0%
New York Tri-State ARea 7,043 14.1%
BOSTON AREA 5,492 11.0%
Washington D.C. Area 4,343 8.7%
San Diego Area 3,329 6.7%
Seattle Area 2,183 4.4%
Los Angelos/Orange County 2,102 4.2%
Iowa 1,440 2.9%
Philadelphia Area 1,041 2.1%
Ohio 1,005 2.0%
Minnesota 998 2.0%
St.Louis Area 987 2.0%
Texas 885 1.8%
Utah 736 1.5%
Geogia 714 1.4%
Indiana 710 1.4%
Colorado 621 1.2%
Illinois 513 1.0%
Other 3,227 6.5%
Total 49,825 100%
-------------------------------------------------------
Source: "Biotech 91: A Changing Environment"
by Steven Burrill & Kenneth Lee, Jr. of Ernst &
Young, 1990.
Table 3.3
GROWTH ESTIMATES FOR MASSACHSUETTS BIOTECH FIRMS
Total Employment, Production Employment and
Percentage Growth 1990-2000
1990
Total Employment
Feinstein
EDIC
13, 600
17,585
Production Employment
Feinstein 3,264
EDIC
1993
21,352
6,300
1995
30,422
2000
79,968
25,655
Percent Increase From 1990
Total Employment
Feinstein
EDIC
Production Employment
Feinstein
EDIC
1993
57.0%
1995 2000
- 488.0%
73.0% -
93.0% - 686.0%
Source: Peter Feinstein, Inc., 1990, (N = 66,
members of the Mass Biotech Council)
all are
Economic Industrial Development Corporation,
"Growth in the Ninties: Prospects for Strategic
Economic Development in Boston", January, 1991.
Table 3.4
Massachusetts Employment Levels
All Industries, Biotechnology, & High Tech
Industry Employment Percent
TOTAL EMPLOYMENT 3,014,700 100.0%
(all industries)
BIOTECHNOLOGY
Ernst & Young 8,000 0.3%
Feinstein 13,600 0.5%
ALL HIGH TECH * 212,200 7.0%
(includes: 36, 38, 376,
379, 357, 348, 283)
Biotech as % of High Tech
Ernst & Young 3.8%
Feinstein 6.4%
-------------------------------------------------------
Source: Total Employment (Bureau of Labor Statistics), includes
all employed people in 1st quarter of 1990.
Ernst & Young, 1990, and Peter Feinstein, Inc., 1990,
both estimates based on industry surveys.
Massachusetts Dept. of Employment & Training, 1991.
'HIGH TECH' defined by MASS DET, includes some non-high
tech.
Table 3.5
Massachusetts High Tech Job Levels
& Job Losses
-------------------------------------------------------
Employment 1989 1990 89-90
-------------------------------------------------------
HIGH TECH (includes 36, 38, 238,600 212,200
376, 379, 357, 348, 283)
JOB LOSSES IN HIGH TECH (26,400)
-------------------------------------------------------
Source: Massachusetts Dept. of Employment & Training, 1991.
'HIGH TECH' defined by MASS DET, includes some non-high
tech.
Table 3.6
US Trends and Forecasts in Biotech & Other High Tech Industries
TOTAL PRODUCTION EMPLOYMENT
Percent Change
EMPLOYMENT 1987 1988 1989 1990 1991 1987-88 1988-89 1989-90 1990-91
Production workers (000) 79.6 81.4 82.3 83.4 83.7 2.3% 1.1% 1.3% 0.4%2833 Medicinals & botanicals 6.1 6.2 6.2 6.4 6.3 1.6% 0.0% 3.2% -1.6%2834 Pharmaceutical preps 59.9 61.6 62.2 62.7 62.9 2.8% 1.0% 0.8% 0.3%2835 Diagnostic substances 6.8 7.3 7.6 8 8.1 7.4% 4.1% 5.3% 1.2%2836 Bio prod ex diagnostic 6.8 6.3 6.3 6.3 6.4 0.0% 0.0% 1.6% 1.6%
3571, -2, -5, -7
Computers & Peripherals 101 105 105 103 101 4.0% 0.0% -1.9% -1.9%367 Electronic Components (including 330 343 333 327 320 3.9% -2.9% -1.8% -2.1%
Semiconducters)
SOURCE: U.S. Department of Commerce: Bureau of the Census; International
Trade Administration (ITA). Estimates and Forecasts by ITA
1988 Advance data from the 1988 Annual Survey of Manufactures.
1989 Estimate
1990 Estimate
1991 Forecast
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TABLE 3.7
Biotechnology Industry
Approval Cycle for a Medical Therapeutic Product
GENERAL ACTIVITY TIME SPAN
Preclinical)
IND
(Clinical
Trials)
Phase I
Phase II
Phase III
Final FDA
Approval
(NDA)
Research and testing on animals
for efficacy & toxicity as well
as replicating production.
Filing of "Investigative New
Drug" application. New data
requests could require 6-12 months
of additional testing.
Tests on healthy humans at
multiple centers to determine
product safety.
Tests on limited group with the
medical problem to determine
product safety.
Test of large numbers of
patients to determine product
efficacy.
Collection, correlation, pre-
paration & submission of test
data and product review.
1 - 2 yrs
1 - 2 mths
1 - 2 yrs
1 year
2 - 3 yrs
1 - 2 yrs
TOTAL 6 - 10 yrs
of Management. Chestnut Hill, MA. 1989.
PHASE
Source: "Biotechnology Industry Analysis," S. Brainard, M.
Podsedly, & L. Sutlif. Boston College Graduate School
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Table 3.8
BIOTECH EMPLOYMENT GROWTH
Pilot & Commercial Plants
Therapeutic Firms
Company Company Company Average Percent
1 2 3 All Firms %
AVERAGE PILOT PLANT
Total employees 40 33 50 41 100.0%
Degreed 28 29 25 27 65.9%
Non-degreed 12 4 25 14 34.1%
AVERAGE COMMERCIAL PLANT
Total employees 40 70 50 53 100.0%
Degreed 12 53 5 23 43.4%
Non-degreed 28 17 45 30 56.6%
Source: Case Studies of 3 Mass biotech firms, 1991.
Data are based on estimates.
Table 3.9
EMPLOYMENT GROWTH BY PRODUCT TYPE IN THERAPEUTICS
during scale-up
Total Employment AVG.
Type of Plant & Product low high
PILOT
Pharmaceutical 15 50 33
Antibiotic 10 33 22
COMMERCIAL
Pharmaceutical (if pilot = 50) 25 30 28
Antibiotic (if pilot = 33) 17 20 18
SOURCE: Case study of Mass. biotech manufacturing, 1991.
NOTE: Commercial employees represent additions to
employees of pilot facility.
Differences between Biopharm & Antibiotic
Therapeutic Products
Biopharmaceuticals Antibiotics
injectable into bloodstream not necessarily injectable
more heavily regulated less regulated than biopharm
more processing steps fewer processing steps
must remove DNA and any purification is simpler
virus in product employs 1/2 - 2/3 number
of employees as biopharm
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Table 3.10
EMPLOYMENT GROWTH FOR DIAGNOSTIC PRODUCT
by Each Production Stage
by workforce degree
R&D Clinical Commercial TOTAL
Total employees 3 2 11 16
Degreed 3 2 0 5
Non-degreed 0 0 11 11
SOURCE: Based on case product for MA diagnostic firm, 1991.
Data are based on estimates.
Note: Degreed = bachelor's plus
Non-degreed = less than bachelor's
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Table 3.11
Biotech Firms & Plans for Consolidation
within the next 5 years
by company size
To Acquire a To
Smaller Firm By
Be Acquired To Merge With an
a Larger Firm Equal-Size Firm
Small
1-50 emp.
Mid-Size
51-135 emp.
Large
136-299 emp.
Top Tier
300 + emp.
All Companies
SOURCE: Ernst & Young, "Biotech 91: A Changing
37.0%
54.0%
76.0%
74.0%
47.0%
48.0%
21.0%
30.0%
22.0%
39.0%
39.0%
17.0%
25.0%
22.0%
32.0%
Environment"
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Table 3.12
REASONS FOR PARTNERING
Biotech Companies with Alliance in the U.S.
Mktg.
Ability
Diagnostic
Therapeutic
Ag-bio
Supplier
All Companies
83.0%
59.0%
46.0%
71.0%
64.0%
Capital New Mfg. Science/
Needs Products Ability Techn'g
29.0%
55.0%
54.0%
31.0%
45.0%
19.0%
10.0%
17.0%
38.0%
20.0%
27.0%
14.0%
17.0%
13.0%
17.0%
10.0%
17.0%
80.0%
80.0%
15.0%
Ernst & Young: "Biotech 91: A Changing Environment"SOURCE:
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Table 3.13
Location of Biotech Facilities
of 11 firms in Massachusetts
Case Study - 1991
MASSACHUSETTS
Same Bldg. 36.4%
Separate Bldg 18.2%
Same City
Separate 27.3%
MA. Cities
NON-MASSACHUSETTS
Separate 27.3%
State
Off Shore 27.3%
SOURCE: Case Studies (1991)
Note: #4 & 5 are not
mutually exclusive
Chapter 4
Skill Requirements
INTRODUCTION
In chapter three, I presented my findings on job growth in dedicated biotechnology
firms (DBFs) and important location trends likely to influence job growth. While policy-
makers are anxious to promote job growth, I have argued that equal attention must be paid to
enhancing opportunities for underserved populations and promoting good jobs. The next
three chapters present the results and analysis of biotech production jobs from the standpoints
of access and quality. Job access is considered in two parts: first in terms of skill requirements
(chapter 4), second in terms of gender and race/ethnicity (chapter 5). Job quality is analyzed
in chapter 6.
In this chapter, the major findings about skills are:
1) Biotech employers are currently hiring nearly twice the proportion of degreed workers
than are represented in the Massachusetts workforce.
2) Despite popular stereotypes, semi- and low-skill jobs do exist in biotechnology firms,
and will increase in the future.
3) Low- and semi-skill jobs are more commonly found in mature firms than R&D firms,
and in diagnostic firms than in therapeutic companies.
4) In addition to education and experience, some entry level jobs require spoken &
written fluency in English, which will prevent some immigrants from accessing these
jobs.
5) Sterile manufacturing techniques and familiarity with Good Manufacturing Practices
(GMP) are transferable production skills to biotech. Some Massachusetts companies
are hiring production workers with these skills from high tech and food processing
industries.
Each of these findings is taken up below in a separate section. In the following
discussion, low-skill means that a high school degree is required, but generally no additional
experience. Semi-skill means that special training and/or an associate's degree is required.
High-skill means bachelors degree or higher.' For ease of presentation, non-degreed is used
from time to time to combine low- and semi-skill. Degreed means education including and
beyond the bachelor's level.
ARE THERE JOBS FOR NON-DEGREED WORKERS?
People often mistakenly assume that all jobs in biotechnology companies require an
advanced degree in the life sciences. While it is true that the industry is very much on the
cutting edge of recent advances in micro-biology, commercial biotech firms must still employ
people to manufacture their products in jobs that do not require 4 years of college.
Table 4.1 presents the research results on education requirements of biotech firms in
my sample compared with the educational attainment levels of the entire Massachusetts labor
force. Because my sample is based on case studies, we cannot generalize about all firms in
Massachusetts, nor about other states. It is likely to err on the side of counting more non-
degreed workers, because older firms (founded before 1982) were deliberately oversampled.
Their workforce is likely to be more diverse in terms of skill than younger firms, who we
would expect to have a larger share of degreed workers.
In table 4.1, we see that the educational composition of the biotech workforce is very
different than that of the entire Massachusetts workforce. While fewer than one-third of
biotech workers are non-degreed based on this sample, almost two-thirds of the Massachusetts
workforce is non-degreed. This difference suggests that a real skill mismatch exists between
the industry and the state's workforce. Most biotech jobs will be inaccessible to most of the
state's residents. However, at least one-third of all biotech jobs (and maybe more if
requirements relax as the industry matures) are accessible to workers with less than a
bachelor's degree.
1 According to this definition, there are several levels of high skill within biotech. There are people with bachelors,
masters, and PhDs. Although these educational differences are significant, they are not relevant to this study.
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If we generalize based on the case studies, then nearly 30% of all jobs in current
biotech firms do not require a bachelor's degree. If we apply this figure to the Feinstein
estimates reported in chapter 3 (refer to table 3.3), then approximately 4,000 of 13,600 current
jobs in biotech are accessible to non-degreed labor. Similarly, if growth projections for the
year 2000 are accurate, then about 22,000 of the 75,000 + jobs will be accessible to non-
degreed labor. However, education requirements are likely to change in favor of hiring more
non-degreed labor, in which case the numbers of jobs mentioned above would be low end
estimates.
Production jobs represent the largest share of all low- and semi-skill jobs found in
firms (usually 60% in the case studies). R&D includes several positions for low-skill labor
(e.g. glass washers) and semi-skill positions (e.g. lab assistants, media preparation technicians,
and animal care personnel), and administration includes clerical support, which can be both
low- and semi-skilled. Clearly, production is the most important area of biotech activity if we
hope to see jobs created for non-degreed workers.
Table 4.2 illustrates the differences between diagnostic and therapeutic firms in terms
of educational attainment levels of the firm's workforce. On average, 25.5% of the total
workforce of the three therapeutic firms in the sample were non-degreed, whereas 42.6% of
all workers in the diagnostic company were non-degreed. All firms in this comparison are
roughly the same age. However, the diagnostic company has been manufacturing for
commercial sale for several years, while the therapeutic companies are either licensing
production of their approved products, or are awaiting product approval.
Job Requirements for Production Occupations
Biotech firms distinguish between low- and semi-skill workers. This distinction has
been largely ignored in recent surveys of Massachusetts biotech companies. If surveys
mention requirements for entry-level positions at all, they generally address semi-skill, to the
exclusion of low-skill jobs. In order to plan to meet present and future labor needs of the
biotech industry, as well as to enhance job access, it is important to understand that there are
different skill needs, and that these needs change over time.
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The rest of this chapter includes three sections. The first section describes the
requirements for semi- and low-skill jobs. The second section describes how skill
requirements change as firms mature. And the third section describes how hiring strategies
have evolved over time, and how biotech firms have coped with skill shortages by hiring
workers from other industries where workers have transferable skills.
SEMI-SKILL PRODUCTION JOBS
Skill requirements vary according to the area of production and the level of
responsibility. While job positions and job titles vary from firm to firm, there is a basic set of
job categories in biotech production, which are listed and grouped by skill level in table 4.3.
Semi-skill positions exist in the areas of 1) process development, 2) cell-culture or
fermentation, 3) separation and purification, 4) aseptic fill, 5) quality control and assurance,
and 6) facilities operation. The semi-skill job titles are typically called manufacturing
technician, instrument technician, and quality control inspector. Employers typically look for
three types of people to fill semi-skilled jobs:
A) Someone who has several years experience (but may not have an associates degree) in
sterile manufacturing and with Good Manufacturing Practices (GMP). Sterile
manufacturing is required by federal law for all human drugs to ensure safety and
effectiveness. Workers must be familiar with the techniques and work environment.
B) Someone who has an Associates degree in biotechnology or related health field (but
may not have previous work experience) where sterile manufacturing and laboratory
techniques are taught.
C) Someone who has a special certificate or license, such as the American Laboratory
Animal Technician's license (ALAS) for handling animals or fireman's license for
boiler operation.
Besides familiarity with federal GMP standards, employers say they want to hire
people who understand the basic equipment including fermenters, cell harvesters, and
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centrifuges. To acquire this knowledge, says one employer, "You don't need a four year degree
person, but you want a skill level that's higher than just high school..."
LOW-SKILL PRODUCTION JOBS
The areas of production that require less skill than those described above, are 1)
facilities operation, 2) assembly, and 3) warehousing & distribution. Sometimes, there are
low-skill, entry positions below the technician level in other process areas as well. These
positions are usually called 'operator' or 'manufacturing assistant.'
Operators, and other entry-level positions, are involved in measurement and
documentation, preparation and transference of solutions, and handling equipment and
supplies. "[An] operator is basically a no-skill job... It doesn't require a rocket scientist to do
it, but it does require someone who is detail oriented, who can read numbers... can understand
decimal points, and can weigh raw materials."
English
Being able to do basic math and follow instructions is not all that is required of entry-
level jobs, say biotech personnel executives. English is also required. Employers say that
because of federal regulations, their employees must be able to communicate and understand
written and spoken directions. Safety considerations were also given as a reason for requiring
English. Several firms said they have had problems in the past with employees whose weak
English skills detracted from the company's operations.
We have a lot of foreign nationals in assembly who speak English, which is required for
safety and instructions... because they have to understand Good Manufacturing
Procedures. Every one of them has to understand that when you switch products, you
literally have to clean up the whole area, get rid of everything on the old lots, and then
check to make sure that when the new batches come in they have the right serial numbers
and so forth.
The language requirement was a consistent theme throughout the interviews regardless
of whether companies were serving diagnostic or therapeutic markets. While language fluency
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may not seem like an unreasonable requirement, it may exclude or limit immigrant workers,
whose English skills may be weak, from gaining employment in certain skill areas in biotech.
Skills Change as Firms Mature
We saw in the previous chapter that production increases in proportion to R&D as
firms mature. Likewise, the requirements for different skill levels also undergo changes as
firms mature. It is important to recall the stages of product development to highlight the types
of skills required at each stage. Opportunities for low- and semi-skill labor increase with each
stage. Table 4.4 shows how the percentage of non-degreed production workers rises from
R&D to clinical to commercial based on data taken from the case studies. The reader should
note that company C in table 4.4 is not yet fully commercial, so we could expect even higher
levels of low-skill labor than are seen at this point.
The skill changes are best described below by the employers themselves:
1) Research & Development - Laboratory Bench:
I consider my entry level here [in R&D] to have a bachelor's degree. It's a
much more highly educated population. Anybody in the lab doing research has
to have at least a bachelor's degree. There are a couple of people in the animal
lab facility who have an associate's degree. Every single other person within
that lab has to have a bachelor's now and will in the future.
2) Clinical Trials - The Pilot Plant:
For the pilot plant, that's different,... the entry level there needs to be at least an
associate's. We could probably get away with a lower level when it gets to
production.
I'd be surprised, if when people were hiring initially for clean room
environments, that they would go to high school educated. The risk you run is
that if you screw up in a regulatory kind of way, you can put yourself in a lot of
trouble. I wouldn't be in favor of doing it. I would want to bring in someone
who has at a minimum some lab experience and understands the environment.
3) Manufacturing - The Commercial Plants:
Once we get to the point where we'll need to have a fully developed production
capability, we know we won't be staffing it with people with biology and
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biochemistry degree holders. It's not driven by the fact that you need people
with those skills. You'll have some of those, but not a predominant number of
them.
Plant managers were even more clear about the changes in skill requirements with each
production phase than were the human resource people. One plant manager said that 1/3 to
1/2 of the pilot plant workforce would be typically be non-degreed, while as much as 90%
would be non-degreed ('or tradespeople') in the commercial plant. Another manager said that
the proportions of degreed and non-degreed in the pilot plant would be 70/30, and then
reverse in the commercial plant.
Before a product can be approved for sale, the production process and facility have to
be licensed. Because of federal requirements for product safety and consistency, commercial
production processes become highly standard and routine. Procedures cannot vary without
risking losing federal licenses to manufacture and sell the product. As a result, skill levels are
higher in the pilot plant where the process is evolving continually, and are lower in the
commercial plant because production has become more routine and automated. The profile of
commercial production also reflects more low skill because additional finishing steps are added
including assembly and packaging, which require no more than a high school degree.
Hiring Strategies Have Evolved Over Time
While product life cycle may offer the greatest explanation of the change in skill
demands from r&d to commercial production, it does not capture the learning process, which
has occurred in older firms. Nor does it explain the variations in hiring strategies among
firms at the similar stages of development. Previous surveys have missed the element of
change occurring within the industry with respect to hiring practices. The biotech industry is
relatively young, and employers learn as they experiment with ways to meet their employment
needs.
In this section, I present some of the hiring lessons learned by the older generation of
firms in my sample (those founded before 1982). These lessons are important for
understanding the industry. Firms have coped with their employment needs in several ways:
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o by hiring people from other states;
o by substituting workers with bachelor's degrees where there is a short supply of
experienced, but nonetheless non-degreed, workers, and
o by re-training workers from other local industries where comparable skills
exist.
But the main pattern is that firms eventually choose to substitute non-degreed labor for
workers with bachelor's degrees.
Since the beginning of biotech, there has been an unusually close alliance between
universities and biotech firms. Many biotech firms were started by university professors and
located near universities. One scientist, who worked with several DBFs (dedicated biotech
firms) during the last decade, said that during those early years, "we were like universities."
The industry-university ties may have influenced decisions about who to hire.
Another employer, with many years experience in personnel, gave this description:
When we were very small, we thought that the person answering the phone should
have a masters in science so that they could understand the questions being
asked. It was that mentality!... If we have a choice between experience and
education, we would probably take education.
When it came time to staffing production areas, many firms went to New Jersey, and
the midwest, to recruit experienced production workers, because there are a large number of
pharmaceutical and chemical companies located there. But relocating people was costly, so
firms decided that recruiting out-of-state was not an effective long run solution to labor
needs. Their next strategy was to hire recent graduates from the universities.
There are several good reasons why firms hired bachelor's degree holders for
production positions. Research scientists were used to working with undergraduate and
graduate students. They wanted people who were familiar with the equipment and practiced
good lab procedures. Furthermore, there has continued to be a large supply of people with BS
degrees graduating from Boston area schools each year.
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Second, there is no pharmaceutical industry in the state from which to hire workers
trained in sterile manufacture. If firms were going to have to train workers, they were more
confident of training bachelor's degree holders than non-degreed people.
The reason we've actually gone after bachelors degrees at these levels is because
we haven't been able to find trained workers. So, we thought that if it was an
option of relocating an hourly paid person, or having a bachelors-level person
for a year or two [who would then move on], we're going to take the bachelors
first.
However, the problem firms experienced with hiring bachelor's degreed people was
that they did not stay long. The jobs the graduates were doing were relatively monotonous
and the opportunities for advancement limited. Firms reported that people were leaving after
one year because they were getting discouraged. While this strategy might have worked in the
short term, companies knew it would be too costly in the long run. Another problem with
hiring recent college graduates is that while they may be familiar with laboratory equipment
and procedure, they still need training with biotechnology equipment. One employer, in a
diagnostic firm, said he preferred not to hire recent college graduates, because they required
training that the company was not equipped to provide.
This isn't a very good place to train people... Previous academic experience is
interesting, but it's not particularly valuable. We take graduates at the entry
level only.
The second strategy was to hire people with high school degrees with experience in
industries where there was some skill compatibility. Employers have hired workers from
industries where sterile manufacturing techniques and GMP practices were followed. Because
of the lack of a developed pharmaceutical industry in the state, they hired operators from the
food processing industry. However, one employer explained that they had problems with
some of the food industry workers, because these workers were used to labor-management
relations based on union contracts, which were unacceptable relations for this firm. The
current hiring strategy among the largest firms is to hire a combination of people, including
bachelor's degrees, associate's degrees in biotech or bio-medical studies, high school graduates
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who have taken a laboratory course, 2 as well as workers from certain industries where skills
may be transferable.
Skill Transferability from Other Industries
Employers are experimenting with hiring semi-skilled labor from other high-
technology industries, such as electronics, pharmaceutical and diagnostic, and chemical, as
well as non-high tech industries, such as food processing. This may be good news to workers
who have lost jobs in the high tech industry (see table 3.5).
People can acquire that experience obviously in pharmaceuticals, but also in food
industries, and we're hiring people out of high tech who have worked in
microchip production...
There seemed to be more interest among firms in trying to hire workers from
electronics than real attempts to do so. At least one major employer thought it would be
feasible for these kind of workers to make the transition.
We can get [production] people trained to operate in clean room environment in
electronics, and transition them into skilled people who can work here. Having
the background of a clean room environment is already an advantage for people
who end up in production here... They ought to be available and trainable without
it being a major issue.
While the majority of the employers in this study expressed the view that skilled
workers from electronics and food industries were suitable for re-training in biotech, some
disagreed. One employer expressed doubts about whether former electronics workers would
be good candidates for biotech jobs. He favored people from other agriculture,
pharmaceutical, diagnostic, and food industries. Another employer even expressed the view
that production operators from other pharmaceutical industries were not as ideal as might be
expected. However, this view seemed to be in the minority.
In most cases they [production operators] haven't been in production facilities
that equate to ours. They're making tablets. We're not necessarily making
2 According to the Boston School Department, there are 1,296 students enrolled in a college-bound, high school
biology laboratory course during the 1990-91 school year. There are also 766 students enrolled in a non-college biology
laboratory course. This group would be among the most likely candidates for entry-level, low-skill biotech jobs.
(Figures are based on reporting by 12 out 16 schools).
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tablets. We're making vials of product which are harvested from different type
of processes. But they do have experience in drug manufacturing.
Training and Future Shortages
The availability of people with special training in biotech production is new as of this
year. The Bay State Skills Corporation, together with biotech companies and several junior
colleges, have designed, funded, and implemented several pilot training programs for biotech
workers at three local junior colleges. The first batch of biotech certificates will be awarded
in 1991. While some of these graduates may go to work in medical research institutions, it is
expected that the majority will work in the private biotech industry.
The high school graduates do not have to have previous work experience, but
employers prefer students who have taken a laboratory course or two. The largest companies
say they have the capability to train workers for their present needs. But several companies
expressed a concern that there could be a skills crunch in the near future as products in the
regulatory pipeline gain federal approval. Once this happens, employers say they will need to
hire more production workers. If several companies reach this stage at the same time, there
could be a shortage.
Given the mix of strategies and opinions, further research into the strategy of
retraining workers from other industries, such as computers, to biotechnology might prove
fruitful. On the other hand, there may also be an opportunity to train people without prior
manufacturing experience for biotech production. Both strategies offer new employment
possibilities to a limited number of Massachusetts workers.
CONCLUSION
The analysis of skill requirements for low- and semi-skill jobs in biotech production
suggests that while there seems to be variation in how firms are fulfilling employment needs,
some patterns have also emerged. The implications of this analysis for low- and semi-skill
labor include:
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1. There are job opportunities in biotech for both low- and semi-skill labor.
2. These opportunities will increase as more firms mature in the next several years.
3. Because other options (i.e., hiring from outside the state, or hiring BS degreed workers
for what are essentially low-skill jobs) are being ruled out, there appears to be a real
opportunity to train a new workforce for biotech in Massachusetts. These workers will
probably include some recent high school graduates.
5. There are probably opportunities in biotech for workers who have been laid off from
production jobs in electronics or food industries, or who may be looking for a change.
6. Most firms do not have the resources nor infrastructure in place to train large numbers
of workers. There may be a skills crunch in the near future if the demand for skilled
labor grows quickly, and existing training programs do not adequately meet that
demand.
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Table 4.1
EDUCATIONAL
Total Massachusetts Workforce
(1990)
LEVEL
vs. Biotech Workforce
Highest Degree Attained Percent
DEGREED
Total MASS Workforce 33.1%
Biotech Workforce Sample 72.2%
NON-DEGREED
Total MASS Workforce 66.9%
Biotech Workforce Sample 27.8%
Source: Current Population Survey, Bureau of Labor
Statistics, March 1990
Mass. Biotech Sample, 4 firms, 1991
Table 4.2
HIGH VS LOW SKILL LABOR
in both Diagnostic and 3 Therapeutic Firms
DIAGNOSTIC
Highest Degree Attained Percent
High Skill Jobs 57.4%
(require BS or more)
Low Skill Jobs 42.6%
(require less than BS)
TOTAL 100.0%
3 THERAPEUTIC FIRMS
Highest Degree Attained Company A Company B Company C
High Skill Jobs 78.8% 77.5% 67.2%
(require BS or more)
Low Skill Jobs 21.2% 22.5% 32.8%
(require less than BS)
TOTAL 100.0% 100.0% 100.0%
Source: Case study data gathered from 4 firms, 1991
High skill = bachelor's + required
Low skill = less than bachelor's
Table 4.3
BIOTECH WORKFORCE BY MINIMUM DEGREE REQUIRED
Massachusetts: 1991
Minimum Degree | Starting
Job Descriptions IPhD BS AA HS I Salary
PRODUCTION
Director X $59,000
Fermentation
Supervisor X $31,000
Reserach Associate X $27,000
Technician X $21,000
Assistant X $18,000
Purification
Supervisor x $31,000
Research Associate | X $27,000
Technician | X $21,000
Assistant X $18,000
Aseptic Fill
Supervisor X $31,000
Research Associate | X $27,000
Technician | X $21,000
Assistant X $18,000
Quality Control
Supervisor X $32,000
Engineer X $32,000
Analyst X $25,000
Inspector X $21,000
Microbiology Supervisor X $32,OO
Microbiologist X $24,000
Validation
Supervisor X $57,000
Technician X $20,000
Quality Assurance
Supervisor X $47,OOO
Documentation Specialist| X $29,000
Technical Writer | X $23,000
Documentation Clerk | x $19,000
SOURCE: Bay State Skills Corporation, Biotech Directory 1991.
Salaries are average estimates provided by MA firms.
Note: There are also a few non-degreed technical support
positions.
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Table 4.4
INCREASE IN NON-DEGREED LABOR
by Stage of Production Development
by date of company founding
R&D CLINICAL COMMERCIAL
SKILL LEVEL Company A Company B Company C
(1989) (1981) (1981)
TOTAL EMPLOYMENT
High Skill Jobs 91.7% 78.8% 67.2%
Low Skill Jobs 8.3% 21.2% 32.8%
100.0% 100.0% 100.0%
PRODUCTION
High Skill Jobs 93.5% 60.0% 37.8%
Low Skill Jobs 6.5% 40.0% 62.2%
100.0% 100.0% 100.0%
Source: Case study data gathered from 3 MASS firms, 1991
High-skill = bachelor's degree + required
Low-skill = less than bachelor's
Chapter 5
Women & People of Color
INTRODUCTION & FINDINGS
In the previous chapter, I analyzed the question of who gets biotech jobs from the
standpoint of skills. An important goal of progressive economic development is to enhance
opportunities for underserved populations. So, in this chapter, I analyze the question of access
from the standpoint of gender and race/ethnicity. No previous study of the Massachusetts'
biotech industry has examined the labor force from this standpoint. It remains an important
question for gauging how future industries will serve the special populations.
Diversity in the workforce has become a fact of life in the US. The composition of the US
workforce is nearly half women and it is expected that in the next century, the majority of new
entrants to the US workforce will be non-white. In Massachusetts, the trend towards racial
diversity is occurring more slowly. Despite this larger trend, high tech industries remain largely
white and mostly male at senior research and management positions (see High Tech Research
Group, 1984).
In a case study of biotech in California in 1983, Ann Markusen noted that the female labor
force in biotech was proportionate to all industries, and minorities constituted 21% of all biotech
occupations. She thought the latter was probably inflated due to the classification of foreign
nationals as minorities in the case study (Markusen, 1983). In my case study, I distinguish
between US minorities and foreign nationals. However, I do not attempt to compare
Massachusetts data with California data, because the California labor force is considerably more
diverse racially and ethnically than the Massachusetts labor force.
The Major findings include:
1) Women occupy nearly half of the science positions in biotech firms in Massachusetts,
which reflects science degrees awarded in the US.
2) Percentages in the sample of women in select occupations are close to percentages for same
occupations for all the US.
3) Minority representation in biotech lags behind other industries, including the US drug
industry.
4) Those minorities in the biotech workforce are mostly in low-skill areas, with a large
number of Asian women in assembly work.
5) There are differences among firms in the female and racial/ethnic composition of the
workforce, suggesting that some firms are more successful in recruiting.
6) Opportunities for minorities in biotech will be enhanced if more minorities are recruited
for training programs and if companies adopt goals for hiring.
The analysis of women in the biotech labor force is presented first, and people of color
second. Throughout the analysis, brief comparisons among firms are made, as are comparisons
between Massachusetts biotech and the US drug industry, all US industries, and educational
attainment in life sciences for women and people of color.
RESULTS
The following analysis is based on information gathered from four Massachusetts' biotech
firms out of the original eleven interviewed for this project. While the case study approach limits
one from generalizing about all biotech firms in the state, the results are still instructive. The
sample probably inflates the presence of people of color in the labor force, because it includes the
largest companies in Massachusetts. Larger firms tend to have more employment in production
activities than small firms. Production jobs require a lower level of education than research jobs,
and the pool of workers from which to hire for these jobs is more diverse as education
requirements drop. It would be misleading to evaluate the younger companies whose main activity
is research and not manufacturing. All of the firms in the sample were founded before 1982.
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The analysis of access in the biotech workforce is based on a set of comparisons. The first
comparison is between the case study data and all drug industries in the US (SIC 283, which
includes biotechnology), to see if the Massachusetts female and minority employment levels in
biotech are higher or lower than the national average for drug industries. Second, I match
occupation data from the sample with US occupational information for all industries to see if
women and minorities are present in certain occupations at higher or lower levels than for similar
occupations for all US industries. The third comparison considers educational attainment to see
what percentage of degrees in the life sciences are earned by women and by minorities. 1
Women in the Biotech Labor Force
Women represent exactly half of the Massachusetts biotech labor force in the four case
studies (see table 5.1). This figure is higher than the percentage of women in the total
Massachusetts labor force (47.3%) for the same year, and higher than the percentage of women
(44%)in the US drug industry (SIC 283) in 1988. The percentage of women in the workforce for
each company in the sample ranges from a low of 41.5% to a high of 60.9% (see table 5.2).
While we cannot perform hypothesis tests because the sample is small and non-random, it
is nonetheless tempting to try to explain the differences between firms. It would seem that the
degree of the vertical integration, or whether a company was in the diagnostic or therapeutic
market sector, would have little effect on how many women work in the company. However,
these differences appear to be significant in the sample. The firm with the largest percentage of
women in its workforce is the diagnostic firm. This same firm is also the most vertically
integrated, because it is doing more commercial manufacturing than the others.
However, vertical integration does not seem to explain the difference between the
therapeutic firms. Therapeutic 3 is less vertically integrated than therapeutic 1, but has a greater
share of women in its workforce than therapeutic 1. Even though therapeutic I is the oldest and
largest firm in the sample, it falls furthest below the mean. Therapeutic 1 is twice the size of
1 The most recent data on education attainment was available for the national level only, with the exception of a
new biotechnology certificate program in progress at three Massachusetts' junior colleges.
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therapeutic 3, and has a much larger production capacity. Present data does not seem adequate to
explain these differences.
Tables 5.3 and 5.4 compare occupation data for the biotech sample with all occupations for
the nation. Women are represented in greater proportions in scientist occupations in our sample
(50.6%) than they are nationally (39.7%). Women are also present in large proportion in technician
occupations. One scientist, from a local firm, observed that:
I think you're going to see a lot of women in the labs. I think there's still all the barriers
and all the old boy networks being formed when you start going up the ladder [out of the
lab and into administration]... I would guess that the more academic organizations are
much less tolerant of women.
After examining the information about who earns life science degrees nationally, it is not
surprising to see a high percentage of women in biotechnology. Women earned slightly less than
half of all advanced degrees in the life sciences (including biology) during the 1986-87 school
year.2 Biology stands in stark contrast to engineering, where women earned only 13.2% percent
of degrees during the same period. Likewise, of all electrical engineers in US firms, only 7.9%
were women (BLS, 1989, Bulletin 2340, p.90).
At junior colleges during the 1986-87 school year, women earned 55% of the degrees
awarded in life sciences nationwide. This spring (1991) in Massachusetts, three junior colleges
will be awarding certificates in biotechnology for the first time. The three participating colleges
have reported their enrollments to the Bay State Skills Corporation, who provided seed funds to
these schools. Women represent almost 60% of the enrolled students (see table 5.6). If this year's
graduating class is typical of future classes, then women will likely enter the production
workforce in greater numbers in the future than at present.
2 "Digest of Education Statistics," the National Center for Education Statistics, 1990.
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People of Color in the Biotech Industry
People of color represent 9.2% of the workforce in the case studies, 3 of whom 4.2% were
African-American and Latino. The most recent data (1988) for SIC 283 showed that the
workforce in US drug industries included 14% minority, of whom 8.5% were African-Americans
and 5.5% were people of Hispanic origin (see table 5.1). Data on Asians in the drug industry's
workforce is not available. Biotech firms in the Massachusetts case studies lag far behind the US
drug industries in terms of the racial and ethnic composition of their workforce.
We can also compare the Massachusetts case study data with the entire Massachusetts labor
force. The Bureau of Labor Statistics (BLS) estimates that minorities4 represent 6.1% of the total
labor force in Massachusetts as of March 1991. If we exclude Asians from the biotech case study,
then the percentage of African-Americans and Latinos in the Massachusetts biotech sample is
4.7% (see table 5.1), which is slightly lower than the statewide average. So by comparison with the
national average for all drug industries, and the total Massachusetts labor force, we see that
Massachusetts biotech workforce is considerably more homogenous.
There is a large difference among firms in the study. The diagnostic firm employed more
minorities than the other three therapeutic firms together. In chapter 4, I reported that diagnostic
firms hire more low- and semi-skill labor, which may account for the differences in the case
studies. Furthermore, the diagnostic company in the sample is manufacturing products for
commercial sale, while the therapeutic firms either license production or do not yet have products
approved for sale. We can see from table 5.2 that the production workforce of the diagnostic
company comprises nearly 70% of the company's total workforce5, whereas production in the
3 Because percentages hide real numbers, the reader should be reminded that the total number of minorities in this
sample of four companies is less than 60.
4 Note: BLS does not gather data for Asians, and there is some overlap in the counting of black and hispanic. So
while 6.1% percent of the total Massachusetts' workforce is minority, it overcounts black and hispanic, and does not
count Asians. A preliminary 1990 state census report estimates that Asians and Pacific Islanders comprise 2.4% of the
state's population.
5 Because the firm reported production and administration together as 'operations,' the estimate for production is
high. Even if we eliminate all of the clerical and professional staff included in operations (several of whom probably do
serve in a production capacity), the production estimate becomes 47% -- still well above the other firms.
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other firms ranges from 15.2% to just under 37 percent. Forty percent of the production
workforce is comprised of minorities in Diagnostic 1, the largest share of which is Asian women
who work almost exclusively in assembly. Production is probably the area of activity in biotech
where the greatest opportunity for diversifying the workforce lies.
There are also notable differences between the three therapeutic firms. In table 5.2 we see
that Therapeutic 1 not only employs the smallest percentage of women, but also the smallest
percentage of minorities, despite the fact that it is older and more vertically integrated in terms of
production than the other two therapeutic firms. Of the three therapeutic firms, Therapeutic 1 is
the only company without an affirmative action plan. Therapeutic 2 has a plan, and Therapeutic
3 is in the process of drawing up a plan. This finding suggests that developing a production
capacity does not guarantee that the workforce will diversify. Company hiring goals and practices
may also make a difference.
The reader should be warned that the number of minorities in certain occupations in the
sample is far too small to allow conclusions to be drawn from it. However, indications about
occupational access can be made. Table 5.6 excludes Asians from the count of minorities by
occupation in the Massachusetts biotech sample, so that Massachusetts data can be compared with
national occupation data, which also excludes Asians. The safest and most obvious conclusion
from table 5.5 is that the diagnostic company shows the greatest diversity in its workforce by
occupational level, while most of the therapeutic firms are more segmented.
Data on minorities earning advanced degrees in biology was not available, but the BLS
reports that the percentage of blacks and hispanics who worked professionally as biological or life
scientists in 1988 was 1.0% and 2.4% respectively (BLS, 1989, bulletin 2340). During the 1986-87
school year, minorities earned 26.8% of the associate degrees in life sciences, which was higher
than the 16% rate of all associate degrees earned by minorities (see table 5.6). In Massachusetts'
junior colleges, 10.5% of the students enrolled in biotech certificate programs are minorities,
which is very close to the statewide population of minorities (estimated to be between 10.2% and
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12.2% -- the first figure probably excludes some hispanics, the other probably double counts some
hispanics).6
From chapter 4, we know that special training is required for semi-skill production jobs,
so state programs will play a key role in helping minorities gain access to these jobs. Although the
program is in its infancy, it is not too early to ask why two schools (University of Lowell and
Massachusetts Bay Community College) succeeded in attracting students of color, and one
(Middlesex Community College) failed to enroll a single student of color. The reason cannot be
that there are no minorities living in the area served by Middlesex Community College.
Lawrence, where nearly 42% of the population is of hispanic origin, is nearby.
While these programs may rely on students to come to them, schools should make a
concerted effort to recruit from underserved populations. Further research into the colleges's
recruitment goals and strategies, as well as student needs (such as transportation) might come up
with valuable policy recommendations for ways to increase minority enrollment, as well as ensure
that students are placed in firms. Schools and employers should work together to help graduates
gain access to jobs in these firms. I was surprised during interviews to learn that some employers
were not well informed about the existing training programs. Better outreach and coordination is
needed to facilitate communication between schools, firms, employers, and students.
CONCLUSION
In answering the original question about who gets biotech jobs?, the preceding analysis of a
Massachusetts biotech sample presents several major implications for women and people of color.
1. Commercial biotechnology is a promising field for women with science backgrounds.
Women have accessed biotech laboratories in larger numbers than most science-based,
private industries. This pattern reflects educational degrees granted in the life sciences.
6 see Massachusetts Institute for Social and Economic Research, UMASS Amherst, 1991. Based on preliminary US
Bureau of the Census data, subject to change before July 15, 1991.
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As long as the number of women earning biology degrees continues to remain high, their
presence in science professions in biotech firms should continue.
2. While women have gained access to the labs, they represent a smaller percentage of
executive and managerial occupations in biotech than in all industries nationwide. This
finding suggests there are stronger barriers to these occupations in biotech than elsewhere,
and that affirmative action goals might help companies address this imbalance.
3. The minority workforce in biotech is minuscule at present. It lags behind both the
national average for the drug industries, and the percentage of minorities in the total
Massachusetts' workforce.
4. Opportunities for people of color to access biotech jobs will probably increase as
companies develop manufacturing operations, where education requirements are lower.
5. The major barriers facing people of color are education requirements, access to training
programs, and absence of hiring goals in biotech firms.
6. Given that a small percent of advanced life science degrees go to minorities, the greatest
opportunities for expanding minority presence lie in low- and semi-skill jobs.
Representation of minorities in semi-skill jobs will likely increase, if the number of
minorities in the certificate programs at junior colleges increases. Likewise, the number
of minorities in low-skill jobs may increase if targeted recruiting from high schools is
done. However, companies that develop affirmative action plans are more likely to hire
more people of color than firms that do not have such plans.
7. Other than efforts in Worcester and at Boston University, training programs do not exist in
many key urban areas, like Roxbury. The feasibility of starting a training program at
Roxbury Community College should be explored. However, given state budget cuts,
community colleges may have to difficulty getting funding. Local biotech firms might be
a source of support for providing or sharing expensive equipment.
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Table 5.1
LABOR FORCE by gender, race/ethnicity
(in percent)
LABOR FORCE US DRUG' ALL2  BIOTECH3
(SIC 283) MASS. SAMPLE
--- (in percent) ---
GENDER
Male
Female
66.0
44.0
52.7
47.3
50.1
49.9
RACE/ETHNICITY
White
Black
Hispanic
Asian
8.5
5.5
94.5
3.3
2.8
90.3
3.4
1.3
5.0
1 "Handbook of Labor Statistics," US Department
of Labor, Bureau of Labor Statistics, 1989.
2 Bureau of Labor Statistics, 1991. Note: There
is some overlap between Black & Hispanic.
3 Data comes from 4 Mass. biotech firms, 1991.
Table 5.2
Massachusetts Biotech Workforce
Race, Ethnicity & Gender
Sample of 4 Firms, 1991
AREA OF --------- Percent ---------- ALL
ACTIVITY DIAG THERAP THERAP THERAP FIRMS
R&D (% of Total Emp.)
Women (% of R&D)
Minorities (% of R&D)
PRODUCTION (% of Total Emp.)
Women (% of Prod.)
Minorities (% of Prod.)
ADMIN (% of Total Emp.)
Women (% of Admin.)
Minorities (% of Admin.)
SALES (% of Total Emp.)
Women (% of Sales)
Minorities (% of Sales)
30.4 38.6 31.3 53.0 38.6
----~8. 46.6-- -- - -
54.3
2.9
50.5 61.9
2.2 4.8
69.6 36.9 33.6
63.7 28.7 51.1
40.0 2.3 6.7
28.6
7.1
15.2
45.0
10.0
46.6
4.2
37.6
46.6
16.8
24.6 22.4 30.3 20.7
* 46.6 60.0
6.9 0.0
(see note)
12.7
58.8
11.8
60.0 53.9
0.0 3.1
1.5
50.0
0.0
3.1
57.9
10.5
ALL DEPARTMENTS 100 100 100 100 100
Women 60.9 41.5 57.5 48.5 50.1
Minorities 28.7 3.4 6.7 5.3 9.2
Foreign Nationals - 3.0 1.5 2.3 1.9
Source: Case Study 4 Massachusetts Biotech Firms, 1991.
* included in production
Note: sales are carried out by parent and alliance
partners respectively.
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Table 5.3
Women in Biotech Workforce by Occupation
MASS Biotech Sample(% of total occupation)
--------------- W o m e n -----------------
Therap. Therap. Therap. Diag. 4 Firm
OCCUPATION Firm 1 Firm 2 Firm 3 Firm 4 AVERAGE
-- ---------------------------------------------------------------------------
Executive, managerial, supervisory 45.0% 38.7% 24.7% 50.0% 39.6%
Scientist (biology) 57.4% 41.3% 50.5% 53.1% 50.6%
Biological technician 44.4% 50.0% 14.3% 50.0% 39.7%
Administrative support, including 93.3% 100% 100% 75.0% 92.1%
clerical
Assemblers 60.0% 50.0% 20.0% 76.5% 51.6%
Production inspectors, testers, 16.7% 100% 66.7% 80.0% 65.8%
samplers & weighers
---------------------------------------------------------------------------
Source: Mass. Biotech sample, 1991.
Table 5.4
EMPLOYED CIVILIANS IN US BY DETAILED OCCUPATION,
Sex, and Race/Ethnicity
Total
Employed
OCCUPATION (000s)
Percent of Total
Women Black Hispanic
Origin
Executive, administrative, & managerial 14,216 39.3 5.6 4
Prof. specialty: Biological & life sciences 75 39.7 1 2.4
Biological technicians 55 42.5 8.2 5.1
Administrative support, including clerical 18,264 80.1 11.3 6.5
Machine operators, assorted materials 2,680 33.5 15.6 13.9
Assemblers 1,141 44.2 14.7 13
Prod. inspectors, testers samplers & weighers 849 51.6 13.9 12.1
Freight, stock and material handlers 1,756 17.5 15.8 8.7
SOURCE: "Handbook of Labor Statistics," US Dept. of
Labor, Bureau of Labor Statistics, 1989
80
Table 5.5
MASSACHUSETTS BIOTECH TRAINING PROGRAMS
Certificate Degree
1990-91 (First Year)
--------------- percent ------------
Program # minority
(location) students female (total) Black Asian Hispanic
Mass. Bay 36 52.8 16.7 8.3 8.3 0.0
(Wellesley)
Middlesex 20 65.0 0.0 0.0 0.0 0.0
(Bedford)
U.Lowell 20 60.0 10.0 0.0 5.0 5.0
(Lowell)
TOTAL 76 57.9 10.5 3.9 5.3 1.3
------------------------------------------------------
Source: Bay State Skills Corporation, 1991.
Note: These programs train people for semi-skill
positions. The
programs have prerequisites that screen for math/science
background.
Table 5.6
MINORITIES IN BIOTECH WORKFORCE,
by Occupation(% of total)
---------------------------------------------- te--------------
-------------- Minorities ------------
Therap. Therap. Therap. Therap. 4 Firm
SELECT OCCUPATIONS Firm 1 Firm 2 Firm 3 Firm 4 AVERAGE
Exec., manager, supervi'y 0.0% 0.0% 5.5% 6.3% 2.9%
Scientist (biology) 0.0% 4.8% 2.2% 0.0% 1.7%
Biological technician 22.2% 0.0% 22.2% 12.5% 14.2%
Administrative support, 0.0% 0.0% 0.0% 25.0% 6.3%
including clerical
Assemblers 0.0% 0.0% 0.0% 8.8% 2.2%
Prod. inspectors, testers, 0.0% 0.0% 0.0% 20.0% 5.0%
samplers & weighers
Source: Massachusetts Biotech sample, 1991.
Minorities = both black and hispanic.
Asians excluded because BLS does not offer comparison data.
Chapter 6
Analysis of Job Quality
INTRODUCTION
Chapter 6 brings to a close the list of questions originally raised about biotech
production jobs. Chapter 3 answered the question: how many production jobs are created as
the production process for a product matures? Chapter 4 and 5 answered the question: who
gets production jobs, from the standpoints of skill, gender and race/ethnicity. Chapter 6
analyzes case study material and secondary material to answer the question: are these good
jobs?
Job quality can be measured in many ways. For purposes of this chapter, I have
gathered information about
o wages and health benefits,
o opportunities for advancement, and
o worker safety.
The last question is raised because there has been considerable controversy surrounding
recombinant DNA research, in particular, the fear of exposure to genetically altered microbes.
Significant findings regarding job quality include:
1) Wages are comparable, but slightly lower than the average for all production workers
in manufacturing industries in Massachusetts. Full health coverage is provided by the
overwhelming majority of companies.
2) Opportunities for advancement are restricted by education, and potentially represent a
real drawback to employees hoping to make a career in biotechnology. There is
evidence of a diversity of opinions among firms about the level of advancement that a
high school person can expect to attain. However, firms are presently encouraging and
supporting employees to continue their education in order to expand their
opportunities for advancement.
3) There is a danger that workers will be exposed to a number of biological, product, and
process hazards, but generally, the industry takes extra special precautions to prevent
accidents.
SALARY/WAGES & BENEFITS
The recent Feinstein survey (1990) reported that the average salary among
Massachusetts biotech firms was $30,700. However, one would expect the average salary to be
high, given the large number of people working in research who have advanced college
degrees. The high average wage for all workers may hide the fact that the distribution of
wages among various occupations is wide. Biotech production workers are probably not
getting rich.
Other recent surveys reported a sample of starting salaries. The Massachusetts Board
of Higher Education Regents (HE) survey reported that people with an Associates degree
could expect to earn between $18,500 and $24,000 (with three years experience), and workers
with a bachelor of science (BS) could earn between $22,000 to $28,000 (with three years
experience). However, so far, surveys have ignored salaries paid to low-skill workers in
biotech. From chapter 3, we know that there are potentially more low-skill production jobs in
a mature biotech plant than semi- or high-skill jobs. Surveys also failed to provide a realistic
estimate of the average production salary in biotech, so that we can compare it to the average
of other industries.
Because biotech production includes some highly educated workers, we can arrive at
an estimate of the average production salary for non-degreed workers by excluding those
positions for which a bachelor's degree (or more) is required (see table 6.1). From a private
industry source, we estimate the average annual salary for Massachusetts biotech production
jobs, not usually requiring a college degree, in 1990 to be $22,235.1 The annual average
salary for all production occupations in manufacturing industries in Massachusetts in 1990 is
1 This source is based on an unpublished, annual industry survey of biotech firms across the nation. The estimate
for Massachusetts is based on information supplied by Massachusetts companies.
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estimated to be $24,106.2 Thus, on average, non-degreed biotech production workers earn
$1,871 less than production workers in all Massachusetts manufacturing industries. If we had
included all biotech production jobs (degreed and non-degreed) in our estimate, the average
salary would be $37,227.
We can also compare Massachusetts biotech hourly wage to the national hourly wage
for all biotech firms (see table 6.2). The US Department of Commerce estimates that the
hourly wage for biotech therapeutic firms (SIC 2836) was $9.25 in 1990, while it was $11.70 in
diagnostics (SIC 2835). We can take the average of SIC 2835 and 2836, which is $10.48 and
compare to Massachusetts biotech, which is $10.51.3 The average Massachusetts' biotech
wage appears to be close to the national average (when we combine 2835 & 2836), but is
considerably lower than the national average for pharmaceutical preparations (SIC 2834,
$13.58), medicinals and botanicals (SIC 2833, $16.82), and all drugs (SIC 283, $12.95).
One explanation for the difference between biotech firms and other drug industries
may be that biotech firms are young and still largely unprofitable. Feinstein reports that only
33% of the companies in the Massachusetts sample showed a profit, and another 10% had
reached break-even (1990: p.29). Once companies become profitable, salaries may begin to
rise. The same phenomenon probably explains why diagnostics pay more on average, because
more diagnostics are profitable than therapeutics. Finally, approximately half of the
established pharmaceutical and chemical industry is unionized, which tends to raise wages.
Local biotech firms are not unionized. One firm was adamant about remaining non-union:
We stay clear away from union people. We just don't want that here. The first time
someone doesn't like something, we don't want them turning to a union. We'd rather they
turn to us and say help us solve it. It's a real concern. We live with some fear of that,
so we're doing everything we can to avoid it.
2 This figure was arrived at by taking the annual average hourly wage for production occupations in manufacturing
industries in Massachusetts in 1990, which was $11.39 and multiplying it, first by the average hours worked per week,
which was 40.7, and secondly by 52 weeks. The first two figures come from the Massachusetts Department of
Employment & Training.
This figure was arrived at by dividing $22,235 by 52 weeks, and 40.7 -- the average hours worked by production
workers in Massachusetts manufacturing industries in 1990.
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While we see that there are differences between degreed and non-degreed salaries in
biotech production, likewise there is a substantial difference in salaries within non-degreed.
On average, a person with semi-skill training in biotech in 1990 could expect to earn $5,605
more than a person in a low-skill position (see table 6.1). The average salary for all semi-
skilled labor in biotech was $24,300 in 1990, compared to $18,695 for all low-skilled labor.
According to a private industry survey, the bottom salary for a low-skill, entry level job, such
as a 'tech I' or 'assembler,' was $13,500 (or $6.50/hour), and the high was $24,232
($11.45/hour) -- nearly twice the low! The most probable explanation for this variation is that
many firms say they fill entry level positions with BS degree holders, whom they must pay a
higher salary (see chapter 4 for a discussion of hiring strategies).
Just because low-skill and semi-skill salaries in biotech are lower than for all
manufacturing in Massachusetts, it does not necessarily mean that these jobs are bad. They
provide full health benefits. All of the eleven firms interviewed for this study provide full
coverage, and most offer worker equity -- not typically available in traditional industries.
Equity may one day be worth a great deal more than was paid for it, and may also may give
workers pride and a sense of ownership for the firm's success.
ADVANCEMENT
I argued in chapter 4 that education attainment, more than experience, delineates job
levels in biotech. The implication is that a worker must gain further education before
advancing in the company. In traditional industries, an ambitious employee might rise from
the shop floor to become a manager. Experience and competence, more than education, were
the tickets to advancement. The same cannot be said for biotechnology firms. The
implication for low- and semi-skill labor is that they will have to return to school for a degree
in order to advance, or face being stuck in one or two positions within the firm, or look for
work in another industry. The implication for employers is that they may have to devise ways
to prevent employees from stagnating and becoming frustrated enough to leave.
Surveys provided anecdotal information about advancement in biotech firms. The
survey by the Economic Development Industrial Corporation (EDIC) of Boston, reports that
there are some cases where a non-lab job might lead to a lab job. It did not specify which
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kind of employee (whether high school or bachelor's) could advance. Furthermore, low-skill,
lab jobs in biotech can be dead-end jobs as much as non-lab jobs. The interviews with firms
provide a rich source of information about opportunities and limits to advancement, as well as
highlighting some interesting differences between firms. At the time of this research, most
firms did not have personnel plans that delineated horizontal or vertical promotions for
employees, although one firm was in the process of developing a plan at the time of this
writing.
There are two types of advancement in biotech, as in most industries. One path is to
move upward, and the other is to move across from one area of production to another. While
there is variation in the advancement paths described by the firms, opportunities for
advancement generally seem to be greater in diagnostic firms, where education requirements
are more flexible. Perhaps this difference is due to the fact that these firms are less heavily
regulated than therapeutic firms giving them more flexibility to move around their employees.
The most common advancement model pertains to therapeutic firms.
VERTICAL & HORIZONTAL ADVANCEMENT
The generic employment structure for the production area of a therapeutic firm
includes five levels -- from operators, on the bottom, to the vice-president at the top (see
table 6.3). Levels 4 and 5 repeat themselves for each process area: cell culture and
fermentation, purification and aseptic fill, and quality control. Generally, a high school
degree is the minimum requirement for levels 4 and 5, but a BS is required for the top three.
Of the three largest therapeutic firms in my study, personnel executives from two of
them said there were possibilities for someone with a high school degree to advance to a
supervisory level (level 2) without additional education, but not much beyond.
[From] the very bottom level, the operator, could probably move up to become a
supervisor, which is the next tier ... Someone with only a high school degree is probably
not going to work their way up the corporate ladder to become the VP of
manufacturing -- no matter how good they are -- because they won't have the theoretical
base.
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Only one major employer of a therapeutic company confidently said that an entry-
level person could rise higher to become the head of supervisors. He offered the possibility
that someone with a high school degree, if ambitious and patient, might even rise to
management levels within production.
[Biotech is] not unlike other mature industries. People [with a high school
degree] can come in and work their way up to a management position -- even
beyond the first level supervisory position. That's going to happen over a span
of time. People can progress through various stages of skill and, eventually,
having demonstrated management and supervisory ability, can be considered and
in fact become supervisors in a management position. From there, it's just a
question of how good they are. They could potentially move laterally over to
some other position in the company. People coming and making a career in
manufacturing tend to stay in those kinds of jobs. After supervisory level, you
tend to see people with bachelor's degrees.
The plant manager of this same company agreed with this assessment. He mentioned several
high school graduates he has working in the plant now, who have been training and are
picking up semi-skill jobs quickly. Their plant manager in Europe is a high school graduate
with 30 years of experience, and "he knows that plant inside and out."
The second type of advancement involves moving horizontally, from one process area
to another. For example, a person working on the assembly line might be asked to move
across to aseptic fill, cell culture/fermentation, or quality control, all of which require
different skills than assembly. Lateral movement occurs frequently in one of the diagnostic
firms in the sample. People can move from assembly to cell culture and then to quality
control. While similar moves are possible in therapeutic companies, most companies in the
study did not describe them as common occurrences. However, it may hold future potential,
as employers find ways to make it work.
It's difficult for somebody to move from packaging into formulation without
experience. We have an effort underway to do more cross training, but it's hard.
We've been so pressured to turn out products. It's easiest and most expeditious to
get the people who have already worked on something to do it again. So the
cross training is a nice idea, but it still needs to happen.
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WORKER STAGNATION
The danger in not having mobility is that people begin to feel that they are stagnating.
Without opportunities to learn new skills and advance, employees begin to get discouraged,
and their productivity may decrease or they may chose to leave. Employers would rather not
have to pay the costs associated with having a high turn-over rate. Production needs to have
stability and continuity, say plant managers. Worker retention is a goal of theirs. However,
the problems with mobility have not been addressed by the industry yet.
I am concerned about the lack of mobility for folks within the production area to
really move up... It's difficult to look to moving up in production when you know
that the boss has a degree that you don't have... We have a tuition reimbursement
program, and we really try to sell it to people in production...
Two other companies mentioned the problem of little advancement. They said it affects BS
degree holders as well as non-degreed workers. The problem is becoming widely recognized
in the industry.
SAFETY
Biotechnology has attracted as much attention for its potentially harmful
environmental and health effects, as for its beneficial effects. Since the beginning, micro-
biologists have taken fairly unprecedented steps to organize themselves to prevent any harmful
effects of their research using recombinant technologies starting with the Asilomar conference
in the late 1960s. They wanted to avoid repeating the history of atomic physicists in the
1940s, whose scientific research was carried out in secret and was eventually put to destructive
uses.
Today, the commercial biotechnology industry has a strong safety record due in part to
efforts by scientists, through the National Institutes of Health (NIH), to develop and
promulgate safety guidelines for recombinant DNA research. However, a recent study of the
occupational safety in biotech remarked that the "informal, overlapping web of mostly
voluntary safety procedures... is hardly a 'safety net,' yet major exposures and flagrant
practices are hardly the norm in biotechnology" (Ducatman et al, 1991, preface).
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While there is self-policing in addition to federal oversight, those people working in
the labs and plants appear to take safety precautions seriously. There are strict standards
regarding facility design and management of the production process. As the level of risk
assessment goes up, requirements for containment and safety go up. The kinds of host
organisms used in biotechnology are such that there is a very small chance that they would
survive outside the lab. However, despite these requirements, workers are still in danger of
being exposed to a number of hazards.
The major categories of biohazards are (for a detailed list, see table 6.4):
1) biological hazards: workers may be exposed to pathogenic organisms, viruses,
and carcinogenic mammalian cells. Besides danger of infection, workers may
experience allergic and immuno- responses.
2) production hazards: workers will likely handle raw materials used in
production, including radioactive materials (e.g. radioisotopes). Overexposure
to these materials is a risk.
3) process hazards: workers work with and around corrosive chemicals and
flammable solvents, which pose risks. In addition, work conditions may cause
injury or stress, due to excessive noise, temperature extremes, slippery
surfaces, and mechanical problems (eg. projectiles).
Production workers in the fermentation and purification areas "encounter risks similar
to those of workers in pharmaceutical and chemical industries, that is, exposure to the final
physiologically active products. Exposures to even minute quantities of certain physiologically
active products may cause medically significant side-effects" (Goldman, see Ducatman, et.al.
1991, p.215). But there are two important outcomes due to the differences between
pharmaceutical industries and biotechnology products. The first is that fewer workers are
likely to be exposed, because biotechnology products are more capital intensive. It takes fewer
people to produce a product. However, the second difference is that biotechnology products
are purer and more concentrated, and therefore, more dangerous. So, workers are at risk of
being exposed to more dangerous products.
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Other workplace hazards include animal handling which may lead to bites or scratches,
or infection by transmittable diseases. The latter may include HIV virus. Finally, there are
physical stresses resulting from repetitive motions and heavy lifting due to inadequately
designed work spaces and work routines. However, these are workplace hazards common to
many industries.
Genetics Institute, Inc., located in Cambridge and one of the nations largest DBF,
participated in a study of workplace injuries between 1984-89. More than 80% of the
accidents were reported due to lacerations, punctures, strains, and burns (see table 6.5a). Most
of job-loss time was accounted for by back injuries and strains (see table 6.5b)
Industry hazards can be controlled through a variety of strategies. The first is to
substitute non- or less- hazardous materials for the hazardous materials. The second is to
engineer solutions that reduce or eliminate the hazards. Third, hazards may be controlled
through proper facility and personnel safety procedures. Medical surveillance of employees
based on a plan that accounts for the specific types of hazards for each work activity is
strongly recommended (Goldman, see Ducatman, et.al. 1991, p.209).
In general, occupational health experts say that while biotech presents potentially
serious effects, they are no worse than those encountered in the past. "Most commercial and
academic laboratories are making efforts at containment and most use safety professionals
routinely. It is reasonable to hope that the biotechnology revolution will have markedly fewer
victims than past technological revolutions" (Ducatman et al, 1991, preface).
CONCLUSION
The major findings about job quality are that:
1) Average annual Massachusetts biotech manufacturing salary is the same as the national
average for all biotech (SIC 2835 & 2836), but is lower than the annual average for all
manufacturing in Massachusetts. However, most of the new biotech companies are
not yet profitable. And many firms also offer company equity at reduced prices.
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2) There is considerable variation in salaries between low- and semi-skill, as well as
within skill areas. This variation is probably due to the mix of degreed and non-
degreed labor in the same job descriptions.
3) Full health benefits are typically provided.
4) Opportunities for advancement exist, but are quite limited for non-degreed labor.
However, there is a difference of opinion about how limiting a high school degree is
for someone in manufacturing operations who is talented and ambitious.
Table 6.1
AVERAGE ANNUAL SALARIES
for Biotech Production Jobs
Boston (1990)
ALL BIOTECH PRODUCTION $37,227
(degreed & non-degreed)
All Semi-skill $24,300
(1-3 years college)
All Low-skill $18,695
(high school)
All non-degreed $22,235
(semi + low-skill)
ALL MANUF'G/MASS (1990) * $24,106
SOURCE: Private Industry Survey, 1990
* Massachusetts Department of
Employment & Training, includes
production jobs only.
Table 6.1
US Trends and Forecasts in Biotech & Other High Tech Industries
AVERAGE HOURLY EARNINGS IN PRODUCTION
(dollars)
Percent Change
EARNINGS 1987 1988 1989 1990 1991 1987-88 1988-89 1989-90 1990-91
Average hourly earnings ($) 12.22 12.73 12.82 12.95 - 4.2% 0.7% 1.0% -
2833 Medicinals & botanicals 15.32 16.09 16.37 16.82 - 5.0% 1.7% 2.7% -
2834 Pharmaceutical preps 12.42 12.98 13.25 13.58 - 4.5% 2.1% 2.5% -
2835 Diagnostic substances 10.74 10.99 11.25 11.7 - 2.3% 2.4% 4.0% -
2836 Bio prod ex diagnostic 8.87 9.02 9.16 9.25 - 1.7% 1.6% 1.0% -
3571, -2, -5, -7
Computers & Peripherals 10.47 10.75 11.16 11.45 - 2.7% 3.8% 2.6% -
367 Electronic Components (including 9.32 9.99 - - - 7.2% - - -
Semiconducters)
SOURCE: U.S. Department of Commerce: Bureau of the Census; International
Trade Administration (ITA). Estimates and Forecasts by ITA
1988 Advance data from the 1988 Annual Survey of Manufactures.
1989 Estimate
1990 Estimate
1991 Forecast
Trade Administration (ITA). Estimates and Forecasts by ITA
TABLE 6. 3
VERTICAL ADVANCEMENT IN TYPICAL THERAPEUTIC FIRMS
by level and degree required
level 1 (BS, MS preferred) Vice President
The top of the production pyramid is the vice-
president of Manufacturing/Operations, who
directs planning and determines budgets, hiring
policies, and programs.
level 2 (BS) Manager or Director
This person overseas the section supervisor,
directs manufacturing operations, and manages
facilities and work schedules.
level 3 (BS) Head Supervisor
All supervisors in level 4 report to the head
supervisor, who coordinates each process area and
its staff.
level 4 (HS + experience) Supervisors
Each 'supervisor' manages a small team of
operators for one of several process areas
(fermentation, separation, purification, aeseptic
fill, and assembly).
level 5 (HS) Operators or technicians
The bottom of the employment ladder is the
'operator' -- or manufacturing assistant -- who
is usually part of a small team of operators.
This person assists manufacturing, including
weighing raw materials, preparing media,
operating machinery, taking measurements,
maintaining GMP records, testing batches, and
packaging final products.
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Table 6.4
POTENTIAL HAZARDS IN THE WORKPLACE:
Biomedical/Biotechnology
TYPES OF HAZARD
Biological
Material
Mutagens and
carcinogens
Solvents/
reagents
Acids and
bases
Gels
Allergens
Chemicals used
in special
experiments
Radiation
Lifting
Repetitive
Motion
Electrical
EXAMPLES
Blood, viruses, and
bacteria genetically
engineered organisms
Alkylating agents,
ethidiun bromide
Phenol, chloroform
methanol, zylenexylene
Sulfuric acid,
hydrochloric acid,
Sodium Hydroxide
Acrylamide monomer
Piperizine, hydrazine
Cyanide & phosgene
Radioisotopes
Materials handling
Twisting caps
High voltage
experiments
POTENTIAL
HEALTH EFFECTS
Laboratory-acquired
infections such as:
tuberculosis
Increased risk of
cancer, reproductive
system toxcity
Headache, dizziness,
skin rash, mucous
membrane irritation
Skin and eye burns
Neurotoxcity
Nasal congestion
skin rash, asthma
Cyanide poisoning,
pulmonary edema
Increased risk of
cancer, reproductive
system toxcity
Acute muscle strain
chronic back pain
Tendonitis
Electric shock
The Occupational & Environmental Health Center
at the Cambridge, MA Hospital, 1988
SOURCE:
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Table 6.5 (a)
BIOTECH WORKPLACE INJURY RECORD
By Type of Injury, and Percentage of Days Lost
from Genetics Institute, Inc., Cambridge, MA
(1984-89)
Type of Injury
Lacerations Strains
Punctures
41.0% 18.0%
Back
Injury
14.0%
Thermal Chemical
Burns Burns
11.0% 60.0%
Table 6.5 (a)
Type of Injury
Back Injury Strains Other
93.0% 60.0% 10.0%
SOURCE: "The Biotechnology Industry -
Occupational Medicine" by Ducatman, et al.
1991
Other
10.0%
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Conclusions & Recommendations
We cannot conclude from this research that biotech is, or is not, good for
Massachusetts. To make a broad statement about the industry would require examining more
topics than labor. Creation of, access to, and quality of jobs for low- and semi-skill labor are
one set of considerations among many. Other issues for consideration might include other
benefits, such as tax revenues, and diversification of the economy, and jobs for high-skill
labor. Negative impacts should be considered as well, such as potential environmental costs.
However, the reader should draw implications from the research about the expectations and
challenges facing economic development strategies based on biotech.
GENERAL CONCLUSIONS
In Chapter 2, I launched this study with a discussion about worldwide economic
competition and the importance given by economic development planners to the set of US
industries we call high tech. The reason high tech industries are favored by most states is
because we think of them as innovative, competitive, and high growth. Innovation is
necessary to be competitive in today's world economy. If industries are competitive, then we
expect them to grow rapidly and provide public benefits, among which is employment.
However, my research into Massachusetts biotech suggests that these expectations may
be overly simplistic. State government and local communities should be better informed about
the particular characteristics of biotech industries, and should be more realistic in planning for
biotechnology. In the following pages, I will address the important lessons learned from the
research, which are:
1. High tech industries are different from each other. Some industries employ
lots of people, while others do not. We must learn to distinguish among high
tech industries.
2. Likewise, not all biotech industries have the same economic and employment
outcomes. We must consider the differences among biotech industries.
3. Manufacturing matters in biotechnology (as in high technology), if jobs are an
important policy goal. Innovation is necessary, but not sufficient to generate
employment for lots of people. Careful economic development planning must
include a strategy for manufacturing.
4. Having a skilled manufacturing workforce is a significant advantage in
attracting, retaining, and developing high tech manufacturing, such as
biotechnology.
Biotechnology industries resemble other high tech industries in that they employ a
larger percentage of scientists than the manufacturing average. They are also highly
innovative and competitive industries. However, biotech is different from other high tech
sectors, such as computers. Biotech manufacturing is less labor intensive than the
manufacturing of computers. Part of the explanation for this is that much of the work in
biotech processes is done by plant or mammalian cells rather than by employees. Another
reason is that the final product in biotech is a vial, or tablet, or test kit -- which has fewer
pieces than a computer. Thus, the first lesson of this research is that not all high tech
industries have the same economic and employment outcomes.
Economic development planners and communities should not expect the same benefits
from different high tech industries. When planning for economic development, they should
be clear about which problems they hope to address through industry development, and be
realistic about which public benefits can be expected. For example, it would be foolish to
expect unemployment problems to be solved by throwing support behind biotech. New jobs
may be created by biotech, but not in large enough numbers to relieve current levels of
unemployment (which are estimated to be around 9.0% in the first quarter of 1991 in
Massachusetts). On the other hand, if enhancing revenues and diversifying the local economy
are goals, then biotech should be able to meet these expectations.
The second lesson of the research is that not all biotech industries have the same
economic and employment outcomes. Biotechnology includes industries that are making
products for diagnosis and treatment of human and animal health, food and agriculture,
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environment, and supplies. This study mostly concentrated primarily on the two largest
biotech market segments: therapeutics (drugs & vaccines) and diagnostics (diagnostic test
kits).'
I concluded that there are significant employment differences between therapeutic and
diagnostic companies. Diagnostic products mature quickly and employ more low- than semi-
skill labor, whereas therapeutic products develop slowly, and employ a mix of low- and semi-
skill labor, but may eventually employ large numbers of people depending on product
characteristics and markets. Company goals may also impact employment growth. Some
companies may pursue the research boutique strategy and not attempt to develop
manufacturing capacities, whereas others will work to become fully integrated.
The implication of this finding is that not only must communities distinguish among
high tech industries, but they must also distinguish among biotech market segments.
Economic development planning should weigh these differences in light of employment needs
and workforce strengths.
Throughout, I have tried to emphasize that manufacturing is as important in successful
biotech economic development as innovation, and that efforts must be made to plan for
manufacturing. There are more total jobs and more jobs for the people who need them most
in biotech manufacturing than in research and development. Opportunities for minorities to
access biotech jobs are greater in manufacturing also. Another argument for the importance
of manufacturing in high tech industries has been made by Cohen and Zysman (1987), who
say that high-wage service jobs develop as a result of manufacturing. "Lose manufacturing
and you will lose -- not develop -- high-wage service jobs."
While strategies to support research, technology development and transfer, and new
company start-ups are critical for developing a biotechnology presence, it is not sufficient to
ensure that full economic benefits from the industry will be enjoyed. Special efforts must be
made to plan for the particular needs that companies have when they begin or expand
1. The 1991 Ernst & Young biotech survey estimated that therapeutics and diagnostics represents 63% of the total
biotech market.
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manufacturing. For specific suggestions, see the section below on policy recommendations
concerning manufacturing.
The final lesson underscores a point that is being made more and more frequently. A
skilled workforce (in this case, a manufacturing workforce, not just an R&D workforce) is vital
to capturing competitive industries, such as biotech. The US has lost many industries to foreign
competition over the last several decades, but, so far, retains competitive advantages in recent
technological innovations, including biotech. Whether we can retain manufacturing depends
in large part on how well we develop the skills of our workforce.
Biotech companies want to hire a mix of entry-level workers -- some workers need to
have basic algebra and English skills, while others need to have special familiarity with
laboratory equipment and manufacturing techniques. However, a national study on education
found that between 1986-88 only 6% of 17 year old students demonstrated the ability to solve
multi-step problems and use basic algebra, and only 8% showed the ability to draw conclusions
and infer relationships using scientific knowledge. 2 Investing in the education and training
of America's workers may be the single most important priority for national and state
governments and private industry. This finding adds weight to the arguments being made
presently against further cuts in the Massachusetts education budget, and goes further to argue
that we should be renewing the public commitment to invest in education at all levels.
POLICY RECOMMENDATIONS
The following policy recommendations are based on the findings of this study. They
are organized and presented according to the four topic areas discussed in chapters 3 to 6:
growth, skills, access, and quality. Chapter 3 included the study of job creation for low- and
semi-skilled labor in biotech manufacturing. Chapter 4 examined the skill and education
requirements for these manufacturing jobs. Chapter 5 evaluated job access from the
standpoint of participation of women and minorities in the workforce. Finally, chapter 6
2 The 1990 National Assessment of Educational Progress, reported in the "Economic Report of the President"
transmitted to Congress in February, 1991.
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considered wages and benefits, opportunities for advancement, and worker safety as indicators
of job quality.
GROWTH
Massachusetts should be more realistic in assessing employment outcomes from
biotechnology. While the state needs positive news at present, it does little good to raise false
expectations about the industry's prospects. If the sober forecast of minor job growth proves
to be an underestimate, then Massachusetts can consider itself fortunate.
Timing is also important. We know from the research that hiring and manufacturing
location decisions occur during scale-up. This finding means that there is a window of
opportunity during which time steps must be taken to meet long-term labor and space needs
of biotech companies. Knowing this timetable can help planners work efficiently and
effectively to maximize the competitive resources of their area to enhance opportunities for
biotech manufacturing.
The time for Massachusetts to act on manufacturing is now, because many companies
will decide where to build manufacturing plants during the next two years. Company
spokespeople say that Massachusetts has not shown as much willingness as other states to
support manufacturing. As a result, many companies are considering manufacturing sites
outside the state.
I am not prepared to argue that Massachusetts should provide free land, favorable
leases, and tax advantages without a more thorough analysis of the costs and benefits of doing
so. Nor am I convinced that Massachusetts can afford to compete with other states on these
grounds. However, there are less costly and more efficient ways for Massachusetts to improve
its competitive advantage.
I would recommend the state consider two major changes to retain manufacturing.
The first includes developing a comprehensive and consistent regulatory framework for
biotech manufacturing based on National Institutes of Health (NIH) guidelines. This change
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will give companies a predictable environment on which to base future plans without worrying
that regulations will change dramatically from place to place or over time. It would also lend
protection and stability to towns and cities who may host these facilities.
The second recommendation would be to designate someone at the state to coordinate
the permitting process for biotech manufacturing. Currently, companies planning to expand
in, or enter Massachusetts have to sort through a complex regulatory system involving several
agencies at different levels of government. I heard numerous complaints from firms that the
permitting process in Massachusetts is disjointed and inefficient. Coordination would simplify
the process and make it appear more friendly to companies.
Besides regulatory and permitting changes, there are broader and more challenging
issues to which industry representatives addressed themselves. Nearly every executive spoke
about the need to resolve the state's fiscal crisis. Another problem frequently mentioned was
the high cost of housing, which makes it difficult for firms to recruit people from outside the
state.
State government is not the only level of government that can plan for biotech
development. Cities and towns can be players too. Worcester provides a successful example.
While Worcester has certain key advantages, including universities and a medical school, it has
also developed and implemented a plan that put all the major components that are attractive to
biotech firms in place. They built a biotech industrial park, adopted NIH guidelines
concerning rDNA research as their regulatory framework, and aggressively recruited
companies. Certificate programs to train semi-skill labor for biotech are also being planned
by local colleges.
SKILLS
Massachusetts must give greater consideration to the education and training needs of
its labor force. The state already has a large, high-skilled labor force. Scientists generally like
living here because of the universities and cultural amenities. If Massachusetts can develop a
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pool of trained semi-skill labor, and develop ways for firms to easily access low-skill labor
coming out of high schools, then firms are more likely to consider expanding inside the state.
Workforce training should be the shared responsibility of the biotech industry, state
government, and the public school system. Training efforts started by Bay State Skills
Corporation and three local junior colleges provide a good role model for future cooperation
between these entities. However, the certificate programs in biotech must have a secure
source of funding to meet the growing demand for semi-skilled labor. Because these are hard
times for state government to find the resources for worthwhile projects, the biotech industry
must look inward to see if it can help finance and support external training programs.
According to employers, there may be a shortage of semi-skilled labor starting some
time in the next two years. As that need increases, some firms may become more willing to
develop internal training, or they may prefer to fund external training to meet their demand
(as they are currently doing to some extent). The state should also consider expanding training
programs to other colleges in the Boston-Cambridge area, in hopes of opening up job
opportunities to people of color living in the City.
Better communication is needed too. I was surprised to learn during the interviews
that some employers were not aware, nor always well informed about the junior college
biotech training programs. The 1990 Economic Development Industrial Corporation (EDIC)
survey also found a lack of awareness among many firms about training programs. And it was
not just the newest and smallest firms which were unaware. The essential information that
firms need to know includes the names of the training schools, program content, number of
graduates, and how to contact them.
Most of the training efforts, so far, have focused on people at the associates degree
level, to the exclusion of high school students. The biotechnology industry association (The
Massachusetts Biotech Council) is making an effort to expand teacher and student awareness
of biotechnology as a science and as a career path. However, there may be more direct ways
to target those students, who have taken at least one laboratory science course but are not
planning to attend college, for entry-level jobs in biotech. One approach to making this
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connection more explicit might be to ask companies to take on student interns for a term or
for the summer.
ACCESS
In general, women have entered biotech science occupations in proportion to their
employment in science occupations for all industries, and in proportion to life science degrees
earned by women. But minorities are underrepresented in most biotech occupations based on
the same comparisons. There are several ways to enhance access to jobs. Much of the
responsibility for improving access is in the hands of employers, who decide where to recruit
and who to hire.
Employers have the final responsibility for the diversity of their workforces.
Presently, the biotech workforce is extremely elite in its educational profile, and homogenous
in terms of its racial and ethnic composition. In many ways, the biotech industry demonstrates
enlightened employment practices. In addition to full health benefits, many firms offer
daycare, employee ownership of stock, and support for continued education. Given these
progressive policies, it is startling to learn that some of the major companies in Massachusetts,
including some that are among the oldest (10 years +), do not yet have an affirmative action
plan.
Biotech companies should develop and implement hiring plans to broaden and
diversify their workforces. The gentlest way to do this would be to publicly recognize those
companies that have established and successfully implemented hiring goals, with the hope that
companies without plans would not want to be left out. A tougher approach would be to
request to see affirmative action plans and implementation results from companies seeking
special tax considerations, and other types of public benefits.
The administrators who recruit and admit students to training programs can also
improve minority access to biotech professions. Junior colleges should be required to do a
better job reaching out to local communities of color. So far, minorities are not well
represented in training programs so far. Sometimes, people overlook the special efforts
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necessary to recruit underserved populations. Recruitment strategies should address specific
attendance barriers, such as transportation, course scheduling (daytime versus evening classes),
and language (need for English tutoring). Some of these strategies may require financial
support.
The state, and cities, should also review land use plans to identify whether there is
land appropriately zoned for biotech manufacturing. Manufacturing is more likely to present
opportunities for low skill labor, and if manufacturing locates near urban labor markets, the
chances of people of color gaining access to these jobs improves. Conscious and well planned
strategies, like that put into action by the City of Worcester, can have an effect on drawing
biotech companies to certain locations, including urban areas. However, proximity to diverse,
urban labor markets is not sufficient to ensure access. Education and progressive hiring
strategies are equally important.
JOB QUALITY
We found that wages and benefits for non-degreed workers in Massachusetts biotech
manufacturing tend to be lower than the annual average of production jobs for all
manufacturing industries in the state. However, wages are likely to increase as firms become
profitable. The greatest drawback in biotech production is that non-degreed workers are
limited to jobs that are more or less dead-end in nature. Again, the onus for solving
advancement shortcomings is on the firms themselves. Undoubtedly, they will come up with
creative ways to enable their employees to develop new skills and advance in the company, if
the alternative is having a high (and costly) turnover rate.
Worker safety is getting more attention as biotech matures. The major
recommendation here is based on advice by occupational health and safety experts (Ducatman
& Liberman, 1991). The current voluntary nature of safety procedures is cause for concern.
Further research and ongoing monitoring of worker health should be conducted by
professionals to fully determine the risks and effectiveness of current safety practices. If it
can be shown that the industry is successfully and adequately monitoring itself, then
additional protections should not be necessary.
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If compliance becomes difficult, one option available to the state would be to adopt
National Institutes of Health guidelines as basis for state law, which would enable the state to
monitor facilities and worker health. Because most firms comply already with these guidelines
(and often go further than the guidelines), their adoption should not prove to be an additional
regulatory burden. However, since the guidelines do not have the force of law now, there is
little room to enforce safety directly.
The good news is that Massachusetts is once again a world center for the research and
commercialization of an important new technology. This fact bodes well for the state's ability
to remain competitive in the world economy. The bad news is that biotech will not save the
Massachusetts economy as we were led to believe. While it may contribute needed revenues
and help to diversify the state's economy, it will not put lots of people to work. However,
biotech can still make a positive contribution to the state's economy and to labor.
Implementing the policies discussed here would help to maximize that positive contribution.
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